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ABSTRACT 
Cancer is the third leading cause of death worldwide, accounting for almost 13% of all 
mortalities. In developed countries, when caught early, cancer is very treatable with high 
success rates for first line treatments. In fact, only about 10% of cancer-related deaths are 
due to the primary tumor, with the other 90% being caused by metastatic or recurrent 
neoplasms. These secondary tumors often present with a reduced sensitivity to 
chemotherapeutic agents, making treatment difficult. Recently, the role of the cell 
microenvironment in informing tumor drug response has begun to be appreciated. 
Despite this, we still lack a comprehensive understanding of this relationship, mostly due 
to the lack of appropriate in vitro models in which to study cancer-matrix interactions. 
With the goal of providing insight to such behaviors, the presented research seeks to 
elucidate the following questions: (1) What effect does a 3D ECM have on cancer cell 
drug response, both at a cell behavior and protein level? (2) Can we promote in vivo-like 
cell-cell and cell-ECM interactions in a biomimetic 3D environment? (3) Does a 
collagen-based 3D culture system recapitulate tissue-specific behaviors of tumor cells? 
And (4) Can we model disease progression by modulating ECM characteristics? 
The presented research attempts to first establish the value of 3D culture systems 
v 
as a model for cancer study, and then use this knowledge to develop and validate a novel, 
biomimetic cancer cell culture platform. In short, cancer cells are grown into large 
spheroids and then implanted into type 1 collagen gels. Advanced fluorescent microscopy 
and protein assays are used to assess cell behavior and drug response. Results indicate 
that by modulating the collagen content of the gels, cell behavior can be directly 
controlled, and that the resultant cell behavior is consistent with previous in vivo studies 
that employed a similar microenvironment. Finally, we show that increasing collagen 
content can be used as a model of breast cancer progression, including developing 
insights into later stage tumors with invasive properties. 
Vl 
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Chapter 1: Introduction 
1.1 Problem Statement 
The ability of tumor cells to resist the effect of chemotherapies has long been a major 
concern of clinical oncologists and researchers alike. Chemoresistance has been 
extensively studied in numerous tumor models, but a complete understanding of the 
numerous proteins and environmental factors that contribute to cancer drug response 
remains elusive. In order to address this knowledge gap, cancer cell behavior and drug 
response must be investigated at the systems level, which necessitates the identification 
of the major effecters of cell fate. Numerous proteins have been identified as potential 
mediators of cancer drug response1- 8, although targeted inhibition of these proteins has 
yielded only minimal success indicating that additional layers of complexity exist within 
the system. In this study, we investigate the role of the cellular microenvironment on 
cancer cell behavior. We believe that extracellular-matrix (ECM) properties, cell-
adhesion proteins and cell-cell interactions play key roles chemotherapeutic efficacy. The 
central hypothesis is that the structural and mechanical properties of the extracellular 
matrix (ECM) affect cell-ligand and cell-cell connections, thus having a significant 
impact on chemoresistance and behavior. 
When investigating cancer drug response in vitro, one of the major themes that 
appears again and again in literature is the need for a comprehensive, biomimetic culture 
model of cancer. Classic culture systems involve the growth of cells on flat substrates, 
typically glass or tissue culture plastic. Although revolutionary when first developed, 
1 
these systems are overly reductionist for investigating complex cellular processes. As 
mentioned above and discussed in detail below, the microenvironment of a cell is just as 
important as a cell itself in determining behavior. Thus, culturing tumor cells on a flat 
plane is not sufficient to recapitulate clinical tumor behavior for controlled study. 
Recently, cancer biologists have benefitted from pioneering work by tissue 
engineers on 3D culture systems9. With increased sophistication in our 2D culture 
techniques, engineers began conceiving of growing whole organs in the lab for human 
transplantation. The first step towards this lofty goal was to promote 3D cell 
macrostructure similar to what is found in the body. Although theoretically revolutionary, 
the practicalities of this type of culture were incredibly complex. Initial work began in 
early 1990s, and over the last 20 years the field of tissue engineering and 3D cell culture 
has grown dramatically. Dimensionality of the cellular environment has been shown to 
drastically affect cell behavior, rendering traditional2D models irrelevant for modem 
studies of complex biological processes. In response, there are now there are hundreds of 
protocols for growing cells on 3D scaffolds, with dozens of different scaffold materials. 
For cancer research, previous tissue engineering studies present an attractive 
platform on which to study clinically relevant tumor behavior. Despite the widespread 
availability of these methods, many drug screening studies are still carried out on 2D 
culture systems. Studies that are carried out in 3D often do not take into account matrix 
stiffness, composition and microstructure, simply assuming a 3D platform in indicative of 
in vivo environments. This oversight is particularly troublesome in cancer research, as in 
2 
vivo tumors are heavily influenced by subtle changes in the ECM, a sensitivity that is not 
as widely appreciated as it should be. 
Tumor development is an intrinsically chaotic process, characterized by 
deregulation and uncontrolled cell behavior. This property of cancer makes 3D systems 
even more challenging. Tissue engineers attempt to induce pre-programmed cellular 
processes in organ development, and are aided by natural homeostasis and negative-
feedback loops that correct for system errors. Cancer cells are characterized by a loss of 
these control systems, and can have strong behavioral reactions to seemingly negligible 
system properties. Thus, when modeling cancer in vitro, it is critically important to be as 
biomimetic as possible, incorporating a natural-like ECM, tumor macrostructure and non-
invasive observational protocols. 
In an effort to advance the field of cancer research and drug development, this 
dissertation presents a quantitative, comprehensive analysis of cell drug response in 
different mechanical environments is carried out. The study is based on previously 
developed 3D cell culture methods based on Type I Collagen gels. This method is 
improved upon by the inclusion of cancer cell spheroids of clinically relevant sizes. The 
spheroid model promotes tumor macrostructure and cell-cell interactions that are not 
present in other 2D or 3D systems. 
1.2 Hypothesis and Aims 
The overarching hypothesis of this dissertation is that varying the biochemical and 
mechanical properties of the ECM, via modulation of collagen content in 3D gels, will 
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affect cancer cell behavior and drug response. Additionally, it is expected that cells will 
show a "preferred" mechanical environment in which they are more robust and drug 
resistant, and that this mechanical environment will correspond to the tissue of origin. 
Finally, we hypothesize that the spheroid model will promote differences in cell behavior 
from sparsely embedded single cells, and can be used as a reasonable in vitro model of 
cancer progression with particular emphasis on tissue-specific metastasis. 
Aim 1 - Characterize cellular response to chemotherapy in collagen gels of different 
mechanical properties. As a baseline for future studies, the effect of collagen content and 
mechanical properties on single cells in 3D is investigated. Cells are subjected to targeted 
inhibition of a key growth pathway, and resulting proliferation is quantified. 
Additionally, the modulation of pathway proteins in response to inhibition, and affected 
by the mechanical milieu, is assayed via western blot. A comparison between a breast 
cancer and bone cancer cell line serves as an indication of whether the model promotes 
differential cell behavior specific to tissue of origin. 
Aim 2 - Develop embedded spheroid model as a reliable platform for drug development, 
delivery mechanisms and cell behavior. Even with the recent advancement of 3D culture 
systems, modem platforms often promote either cell-cell or cell-matrix adhesions, but not 
both. This model attempts to address this deficiency by embedding a large cancer cell 
mass inside the 3D collagen gels from Aiml. This allows for the study of how ECM 
properties and mechanics affect a more biomimetic tumor system. The model's 
robustness, reproducibility and throughput are characterized. A quantitative study of 
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spheroid growth in different mechanical environments is carried out, in both a breast and 
bone cancer cell line. Finally, engineered drug delivery methodologies are validated in 
the spheroid model, and compared to results to in vivo and 2D systems. 
Aim 3- Validation of the embedded spheroid model as a tissue specific analog. Most 3D 
systems do not attempt to create a tissue-specific microenvironment, utilizing a one-size-
fits-all approach. This weakness is addressed by the use of varying collagen densities as 
tissue-analogs. Bone cancer spheroid growth, migration and protein expression is 
quantitatively studied over a range of mechanical environments, with increased cellular 
robustness and drug resistance expected in the bone-like stiffer gels. 
Aim 4 - Metastatic breast cancer in the embedded spheroid model. Tumors often 
preferentially metastasize to certain tissues, but this process is poorly understood. To 
further the understanding of this preference, this aim uses different collagen gels as tissue 
analogs and the behavior of pre- and post-metastatic breast cancer cell lines are 
investigated. The post-metastatic breast cancer cells have a well-documented preference 
for metastasizing to bone, with the stiffest collagen gels presenting a similarly attractive 
colonization environment. Spheroid growth, cell extravasation speed and protein 
secretion are studied to elucidate mechanisms of tissue-specific metastasis. 
1.3 Structure of Thesis 
This thesis will provide detailed background on clinical cancer properties, the ECM and 
its effects on cell behavior, and 3D culture systems in the next chapters (Chapters 2-5); it 
will then discuss the experimental and computational projects that address the aims 
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detailed above (Chapters 6-8); and fmally conclude with some closing thoughts and 
directions for future work (Chapter 9). 
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Chapter 2: Cancer 
Cancer is the second leading cause of death in United States, with 1 in 4 deaths being 
attributed to the disease10. Worldwide, cancer is the leading cause of death, accounting 
for 13% of all mortalities 11 . Cancer is an umbrella term used to describe many distinct 
diseases that all involve unregulated cell growth cause by genetic abnormalities. The vast 
majority of cancers are classified into one of three broad categories based on their tissue 
of origin. Carcinomas arise from epithelial cells with comprise the skin and internal 
cavity linings of the body. Carcinomas are by the far the most common type of cancer, 
with most presentations of breast, lung, prostate, pancreas and colon cancer being some 
form of carcinoma. Sarcomas arise from connective tissue such as fat, bone, cartilage and 
nerve tissue. The research presented in this dissertation uses in vitro models of breast 
carcinoma and bone sarcoma. Leukemia's and lymphoma's arise from hematopoietic 
cells that develop in the blood or lymph nodes respectively12. This chapter will serve as 
an introduction to the commonalities between all cancers, with a specific focus on what 
makes them difficult to treat. 
2.1 Hallmarks 
Despite their classification as a single disease, every tumor is genetically unique making 
it very difficult to develop universally efficacious treatments. Despite this variety, 
decades of research has led to the identification of characteristics shared by every tumor. 
These "hallmarks" of cancer were first articulated in the famous 2001 review article by 
Hanahan and Weinberg13 • The original6 hallmarks were identified as [1] self-sufficiency 
in growth signals, [2] insensitivity to anti-growth signals, [3] evasion of programmed cell 
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death, [4] limitless replicative potential, [5] sustained angiogenesis, and [6] tissue 
invasion and metastasis. 
2.1.1 Self Sufficiency in Growth Signals 
Normal cells require the application of specific biochemical cues in order to enter a 
proliferative state. In the absence of these signaling compounds, cells are quiescent and 
metabolically inactive. This characteristic is of vital importance for normal tissue, organ 
and organism development. Cells sense these growth factors (GFs) using transmembrane 
or cytosolic receptors, which bind a particular chemical compound and induce activity in 
downstream protein pathways. These pathways then lead the cell to express genes leading 
to increased metabolic activity and mitosis. Cancer cells liberate themselves from this 
dependence, leading to deregulated growth. Cancer cells often acquire to ability to secrete 
GFs they are sensitive to, termed autocrine signaling. Most cells are not capable of 
producing their own GFs, relying on the diffusion of GFs produced at distant sites 
(paracrine signaling). Examples of this include Wnt signaling in breast and colorectal 
carcinoma as well as ovarian cancers14, IL-6 in lung adenocarcinoma15, and VEGF/TGF-
~ in breast cancers16•17. Abnormal growth factor receptor expression or activity has also 
been implicated in the increased proliferation of many different types of cancers. Many of 
these receptors are in the receptor tyrosine kinase family of proteins. These receptors 
phosphorylate tyrosine residues on nearby proteins in response to growth factor binding, 
allowing those proteins to disseminate proliferative signals to the cell. Often, mutations 
or over-expression of these receptors results in constitutive kinase activity leading to 
pathway over activity. Epidermal growth factor receptor (EGFR) has been found to be 
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mutated and/or overexpressed in many forms of head, neck and stomach cancer13' 18. 
Other commonly mutated receptor tyrosine kinases include vascular endothelial growth 
factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), insulin 
receptor (IGF-lR) and fibroblastic growth factor receptor (FGFR)19. Extreme over-
expression has also been shown to induce ligand-independent signaling in some cases20. 
Cancer cells can also produce a mutated, constitutively active downstream protein. These 
mutations, result in protein signaling pathway deregulation leading to unconstrained cell 
growth. Mutated Src has been implicated in glioblastoma21 . Additionally, the Ras 
subfamily, a group of small, regulatory GTPases, is the most commonly mutated 
oncogenes in cancers, being found in 20-25% of all tumors and up to 90% of all 
pancreatic tumors22'23 • 
2.1. 2 Insensitivity to anti-growth signals 
The induction of cell quiescence is not only a passive process occurring in the absence of 
growth factors, but can itself be actively induced by the presence of growth inhibitors. 
These molecules, like growth factors, activate cell surface and cytosolic receptors that 
lead to downstream behavioral effects. Most inhibitory proteins induce a signaling 
cascade that is associated with cell cycle regulation. A strong anti-growth signal causes a 
normal cell to enter the Go phase, or to enter a permanently post-mitotic state. Cancer 
cells are characterized by their ability to ignore or circumvent these signals. This often 
results from a mutation in a tumor suppressor gene, which normally responds to growth 
inhibition signals to prevent cell growth. Cancer cells can also down-regulate integrins 
and cadherins, which are responsible for anchoring cells to the extracellular matrix 
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(ECM) or other nearby cells. Loss of these proteins prevents the cell from sensing high 
local cell densities, a condition called confluence that normally results in arrested cell 
growth. 
2.1. 3 Evasion of programmed cell death 
Programmed cell death, or apoptosis, is a normal cell function that is constantly occurring 
throughout the body. It is distinct from necrosis, which is traumatic cell death. Cancer 
cell population increase is attributed not only to increased growth rates, but to reduced 
death rates as well. It is believed that apoptotic machinery is present, at least in latent 
form, in virtually all mammalian cells13 . Cells undergoing apoptosis are digested from 
within by proteases and nucleases, which degrade the cell membrane, cytoskeleton and 
chromosomes24 . Leftover cellular debris is phagocytosed by nearby cells within hours25 . 
In normal cells, apoptosis can be triggered by either the intrinsic and extrinsic pathwal6. 
The extrinsic pathway is mediated by Death Receptors (DR) that respond to apoptotic 
signals in the extracellular environment. This leads to downstream assembly of the death-
inducing signaling complex (DISC). One of the proteins in the DISC, cysteine aspartyl-
specific protease 8 ( caspase 8), undergoes autocatalytic cleavage, causing it become 
active27 . This in tum activates downstream effector caspase proteins (3, 6, and 7) which 
lead to the characteristic changes of apoptosis. 
Apoptosis is more commonly triggered internally, in response to cataclysmic 
cellular malfunction, including DNA damage, protein signaling deregulation or hypoxia. 
This intrinsic pathway is mediated by the release of apoptogenic factors, including 
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cytochrome c, from the inter membrane space of mitochondria. The release of these 
apoptogenic factors results in the formation of the apoptosome, leading to the auto-
activation of the initiator caspase 9. Caspase 9 then activates effector caspases 3, 6, and 7 
leading to cell death. The intrinsic pathway is controlled by interactions between anti-
and pro-apoptotic Bcl-2 family members which share homology via their BH-3 
domains28 . The multi-domain pro-apoptotic Bcl-2 family proteins Bax and Bak are 
essential for mitochondrial apoptosis and their activity is controlled by the BH-3-only 
pro-apoptotic Bcl-2 family proteins. Two models have been suggested for this activation 
ofBax and Bak. In the 'direct model ' , BH-3-only proteins directly activate Bax and Bak, 
whilst in the 'indirect model' BH-3-only proteins bind to anti-apoptotic family members 
(such as Bcl-2 and BclXL) and prevent them from binding to and inhibiting Bak and 
Bax1• 
Critically, this machinery can detect the development of one of the first two 
hallmarks of cancer and prevent these mutations from propagating. Thus, cancer 
progression necessitates this insensitivity to apoptosis. By far the most well known 
cancer-associated mutation is the loss of function p53 gene, which is found in >50% of 
all cancers29. Li-Fraumeni Syndrome is caused by the inheritance of one faulty copy of 
the p53 gene at birth, and is associated with an order of magnitude increase in lifetime 
cancer risk30. 
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2.1. 4 Limitless replicative potential 
The evasion of normal regulatory mechanisms should, in theory, allow malignant tumors 
to form arbitrarily large cell masses, however; one last safe-guard must first be breached. 
Mammalian cells have a built in limit to the number of times they can replicate their 
DNA, termed the Hayflick Limit31 . This limit is between 40 and 60 cell divisions, and is 
caused by the inability of DNA polymerase to add base pairs to the 5' end of DNA; 
causing chromosomes being shortened by 50-1 OObp every replication cycle. Eventually a 
critical loss of DNA occurs, and replication can no longer occur. This state is referred to 
as senescence. Genetic manipulation and extensive pro-growth signaling can induce 
senescent cells to continue dividing, but they quickly reach a physical limit, termed crisis, 
in which end-to-end joining of chromosomes occurs resulting in massive cell death. 
Despite these built-in limits, cancer cells are often immortal, meaning they never reach 
senescence. This is most often achieved through increased expression telomerase, a type 
of reverse transcriptase which adds DNA to end of chromosome, replacing their 




2.1 . 5 Sustained angiogenesis 
Angiogenesis, the growth of new blood vessels, is a critical biochemical pathway during 
development, and is carefully regulated in adulthood. There are dozens of pro- and anti-
angiogenic factors, and vessel growth is only stimulated when the balance of signals tilts 
towards pro-angiogensis. Virtually all cells in the body are found within a few hundred 
microns of a capillary blood vessel. This proximity is critical from nutrient and oxygen 
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delivery as well as waste removal. Cutting off this lifeline results in hypoxia leading to 
necrosis, which cancer cells are unable to prevent. Therefore, without the growth of need 
blood vessels, neoplasms have a size limit before cell growth is counterbalanced by cell 
death. Most early tumors reach this stage, at which point cell turnover becomes 
incredibly rapid33 . The hypoxic environment puts extreme selection pressure on the cell 
population, eventually leading to the production of pro-angiogenic factors , most notably 
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). These 
growth factors bind receptors on the endothelial cells lining vessel walls, causing them to 
proliferate. This is also associated with increase ECM degradation, leading to vessel 
spreading the release of more pro-angiogenic factors that had been immobilized in the 
ECM. This process allows the tumor to recruit a sufficient blood supply34. This process is 
known as the angiogenic switch, as it represents a discrete step in tumor progression 13• In 
normal angiogenesis, vessel sprouting is followed by vessel maturation involving the 
recruitment of smooth muscle cells. These cells stabilize the nascent vessel and prevent 
leaking. This step is absent in many cancers, leading to "leaky" vessels35 . This 
characteristic is important in tumor cell invasion into the vasculature for colonization of 
distant sites. 
2.1. 6 Tissue invasion and metastasis 
The development of distant, secondary neoplasms is believed to be an inevitable 
progression of cancer if no treatment is administered 13. Metastasis is the cause of 90% of 
human cancer related death13 • Eventual development of metastases is the reason that early 
cancer detection is critical in patients. If the cancer is not discovered until metastatic 
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lesions have arisen, survival rates are almost always low. Metastasizing allows the cancer 
cells to escape the nutrient-limited environment of the primary tumor. Subsequent 
colonization of nutrient-rich areas as well as recruitment of local stromal cells resulting in 
incredibly robust neoplasms that are very difficult to treat. 
The fact that most types of cancer have preferred metastatic organs indicates that 
this process is not stochastic but involved the acquisition of specific cellular traits36. In 
order to form metastases, cancer cells must acquire the ability to break off from the 
primary neoplasm, invade the circulatory system, subsequently escape circulation and 
colonize a distant site. Breaking off from the cell mass requires to loss of cell attachment 
mediating proteins, such as E-cadherin and integrins. These proteins are often lost earlier 
in cancer development, as described above. Loss of E-cadherin, but not integrins, is one 
of the staples of epithelial-to-mesenchymal transition, by which a carcinoma cell loses its 
epithelial morphology in favor a more mobile mesenchymal morphology. Mesenchymal 
cells are characterized by a polarized morphology consisting of protrusions such as 
lamellipodia, filopodia and invadapodia in response to increased cytoskeletal-actin 
remodeling. These protrusions are able to bind to the ECM and propel the cell rapidly. 
This type of migration is also dependent on ECM degradation via matrixmetalloproteases 
(MMPs). Loss of both E-cadherin and integrins results in a different type of cell 
migration called amoeboid migration. These cells have a round morphology, and are able 
to deform their cytoskeleton to squeeze through ECM pores without requiring prior ECM 
degradation. Invading cancer cells are often not locked in to one type of migration, as 
inhibition of mesenchymal migration can induce the cells to migrate in an amoeboid 
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fashion and vice versa37•38. More recently, the ability of cancer cells to migrate and 
invade in small clusters of 5-l 00 cells has been appreciated39. These cells have not lost E-
cadherin expression, allowing them to maintain tight cell-cell contact. These cells are 
able to form multicellular contractile bodies that propel the cluster forward. 
2.2 Drug Resistance 
Less than 1 0% of all cancer related deaths are due to the effects of the primary tumor, 
indicating that initial treatments are usually highly effective40. The two main causes of 
death are distant metastases and tumor recurrence after remission, often associated with 
resistance to chemotherapy. Acquired drug resistance in tumors was first observed almost 
50 years ago, when it was noted that only 0.5% of patients achieved complete remission 
after treatment with a single therapeutic agent, and the majority of this subpopulation 
eventually relapsed despite continuing treatment with the initially effective therapy 
strategy41 . This failure of single agent therapies is attributed to a population of tumor 
cells which become insensitive to the single agent, rendering further treatment 
ineffective. Additionally, cancer cells may exhibit intrinsic resistance, which is 
characterized by decreased sensitivity to a drug even without previous exposure 
Thousands of studies have been undertaken with the goal of understanding and 
circumventing resistance in cancer cells. Although much has been learned, the ability to 
anticipate and prevent the development of chemoresistance is still not possible. 
Perhaps the most well-known recent case of chemoresistance foiling the success 
of a therapeutic is the case ofimatinib mesylate (Gleevec®; Novartis). This drug was 
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developed as a specific inhibitor of the Bcr-Abl fusion gene product, which is the 
hallmark of Chronic Myeloid Leukemia (CML). It was initially considered a "magic 
bullet"42 for the treatment of CML, and produced dramatic improvement in a large 
number of patients. This impressive early success led to rapid FDA approval and a huge 
amount of media attention. Unfortunately, this success was short lived, as many ofthe 
patients eventually relapsed. Not only did the leukemia return, but there-emergent 
leukemic cells were resistant to Gleevec, precluding further Gleevec treatment for this 
subset of patients. Today Gleevec is still used to treat early stage CML, but it is no longer 
'd d . 1 43 cons1 ere a m1rac e cure . 
The conventional metrics used to evaluate the performance of anti-cancer agents 
leave much to be desired. One of the classic end points used to evaluate drug efficacy is 
50% reduction in solid tumor mass44 . Reduction in tumor mass is relatively easy to 
accomplish, but the subsequent drug-resistance associated relapse is often ignored 
completely with these types of assay. Besides mass/volume measurements of the solid 
tumors, there are few quantitative measures that are taken from this model. This 
introduces issues for both reproducibility and comparisons between different agents. It 
also precludes investigations into the mechanism of a drug's action, which is often done 
in the 2D in vitro models. 
2. 2.1 Cancer Stem Cells 
Although there have been many advances in chemotherapy over the years, advanced 
stage malignancies often remain stubbornly incurable. Treatment of these tumors is 
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almost always associated with short-term regression followed by relapse. Advanced 
tumors consist of a highly heterogeneous cell population, with only a small percentage of 
cancer cells retaining proliferative activity when removed from their normal host45 . This 
subpopulation of cells has recently been implicated in the persistence oftumors46. These 
cells, called cancer stem cells (CSC), retain features of normal stem cells including self-
renewal47, pluripotency48, and altered gene expression49. 
CSCs were recently isolated and purified from the CD133+ cell fraction of brain 
tumors, and the isolated cells were able to form morphologically similar tumors to the 
ones they were harvested from50. In a colorectal cancer model, CSCs were found with a 
frequency of 1 in 5.7x104 cells, but were significantly enriched in the CD133+ fraction (1 
in 200 cells)51 . In breast cancer, CD44+/CD24(low) cells are able to form tumors in SCID 
mice with as few as 100 cells injected. Compared to the 1 0,000+ cells normally required, 
these cell are markedly better at forming neoplasms and are hypothesized to drive tumor 
growth in humans52. Similar findings arose in ovarian cancer, where as few as 100 
CD44+/CD 117+ cells were found to be tumorigenic, whereas > 105 CD44-/CD 117- cells 
were unable to form a novel tumor. Additionally, the tumorigenic cell population showed 
increased resistance to cisplatin and paclitaxil as well as upregulation of stem cell 
markers53 . CD44+/CD24+ pancreatic cancer cells had 100-fold increased tumor forming 
capacity, and the tumors formed were histologically identical to the original tumors54. 
Finally, CD133+/CD44+ prostate cancer cells exhibited similarly increased 
tumorigenicity. Interestingly, these cells lack the androgen receptor that is targeted in 
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prostate cancer hormone therapy, indicating that this therapy fails to target the stem 
cells55 . 
Among the up-regulated genes found in CSCs are those that mediate exogenous 
drug export, DNA repair, anti-apoptosis and proliferation56. These are precisely the 
biochemical mechanisms implicated in chemoresistance 57, suggesting that resistance to 
anti-tumor therapy may arise from the sub-population ofCSCs58. Further complicating 
the situation, the specific genetic and epigenetic state of individual CSCs is highly 
heterogeneous within the tumor CSC population59. Heterogeneous cell populations are 
incredibly difficult to treat, as specificity and efficacy are not achievable across the entire 
population60•61. Additionally, CSCs can give rise to poorly differentiated daughter cells 
which are highly susceptible to the epithelial-to-mesenchymal transition (EMT), a 
process which produces highly invasive and metastatic cells62. 
The existence of CSCs also has many implications for the development of new 
anti-cancer agents. Currently, a major end-point goal of animal studies and clinical trials 
is the 50% reduction of tumor mass63. CSCs, being more resistant to therapies, are most 
likely enriched in this 50% smaller tumor, meaning that aggressive relapse is highly 
probable despite the initial efficacy of treatment. CSCs can also be used for molecular 
· profiling of tumors. Recent evidence suggests that the behavior of tumors can be 
predicted by the early stage epigenetic state of the subpopulation of CSCs64. This 
application could also be extended to the analysis of metastasis. Many tumors spread to 
distant sites, but not all remote colonies turn malignant. The aggressiveness of a 
metastatic colony is associated with an enriched esc population65, indicating that this 
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could be used as a metric to assess whether a metastatic lesion is benign or malignant. 
2. 2. 2 Hypoxia and Drug Resistance 
In normal tissue the design of the blood vessels is such that optimal blood flow occurs 
under virtually all circumstances meaning that most cells experience only transient 
exposure to low levels of oxygen. In tumors the newly formed blood vessels are much 
less effective at providing adequate oxygenation and hypoxia, a drastic reduction in 
oxygen levels, is a common finding 66. These vessels are often lacking enervation, highly 
permeable, and are prone to blind ends and excessive branching67•68 leading to hypoxia 
that can be long lasting (chronic) or transient (acute). Furthermore the oxygen delivery to 
tumor cells is very inconsistent and oxygenation levels within a tumor can be highly 
heterogeneous. Hypoxia can contribute to drug resistance in a number of ways. The most 
direct link is that the reduced blood flow and poor tissue perfusion result in decreased 
bioavailability of administered drugs. This leaves intracellular drug concentrations lower 
than anticipated. Additionally, many chemotherapeutic agents target DNA replication and 
cell cycle pathways and are thus more active against highly proliferative cells. Hypoxic 
cells tend to divide more slowly, and are therefore less sensitive to these types of 
therapeutics69. Radiation therapy suffers from similar problems, as a major method of 
radiotherapy-induced cell death is via the formation of reactive oxygen species (ROS). In 
hypoxia there is less oxygen to convert into ROS, so the cells are insensitive to this kind 
oftreatmene0. Additional mechanism of hypoxia-mediated drug resistance are more 
indirect, but no less potent. Low oxygen levels stimulate genetic and epigenetic responses 
mediated by the activity ofhypoxia inducible factor (HIF)-1. HIF-1 is on~ ofthe most 
19 
widely studied transcription factors, and has been implicated in the control of over 60 
genes, most of which are involved in survival mechanisms including angiogenesis, 
proliferation, anti-apoptosis, and metabolism 71 . Many of these genes are also associated 
with a cancerous phenotype when overexpressed71 . Tumor cells constitutively expressing 
HIF-1 are highly invasive, while HIF-1 silencing with small interfering RNA (siRNA) 
drastically reduces invasiveness72. Resistance to cytotoxic agents in hypoxia has been 
observed in a wide range oftumor types, and in most cases it is dependent upon the 
function of HIF -1 . This resistance can be reversed by strategies that inhibit HIF -1 73- 76 . 
Therapies aimed at overcoming hypoxia-mediated resistance have taken two forms: 
prodrugs that are enzymatically converted to their active form preferentially under 
hypoxic conditions (otherwise known as bioreductive agents) and small molecule 
inhibitors ofHIF-1 activity. Bioreductive agents rely upon the increased activity ofthe 
cytochrome P450 reductase system under hypoxic conditions, resulting in increased 
concentrations ofthe active metabolite within hypoxic tumors. By far the most successful 
example of this strategy is tirapazamine (TPZ). TPZ is activated across a wide range of 
oxygen levels, rather than being limited to only the most severely hypoxic regions of 
tumors. 77 . The inhibition ofHIF-1 has been explored in several reviews78'79, but to date 
only one molecule has entered clinical trials80 . 
2.2.3 Cell Adhesion Mediated Drug Resistance 
Cell Adhesion Mediated Drug Resistance (CAM-DR) is a multidrug resistant phenotype 
promoted by cell-cell and cell-ECM interactions81 • CAM-DR that arises from cell-cell 
interactions has been coined multicellular resistance (MR)82, and was first observed when 
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experimental evidence showed that multicellular spheroids were more resistant to 
radiation than cells in monolayer83 . Subsequently it has been shown that these spheroids 
are also resistant to a range of mechanistically disparate cytotoxic drugs 84-87• This 
increased resistance is mediated through E-cadherin, a cell-cell adhesion molecule; 
multicellular spheroids treated with E-cadherin blocking antibodies become highly 
sensitive to cytotoxic agents, while E-cadherin blocking in 2D cell cultures had little 
effect on drug sensitivity88. This suggests an intriguing area for development of new 
therapeutics, but this strategy has yet to be fully explored89. Cell-ECM interactions also 
have been shown to promote tumor cell survival and decreased sensitivity to cytotoxic 
agents. This is mediated through integrins and other surface proteins such as CD4490. 
Integrin expression has been implicated as an indicator of chemoresistance91 , and CD44 
is overexpressed in certain tumor celllines92 . Additionally, abolishing cell-ECM 
adherence leads to a specific form of cell death called anoikis, even without the activity 
of a cytotoxic drug93 . Laminin, fibronectin and collagen have all been shown to have pro-
survival abilities when interacting with cellular integrins94 • 
2. 2. 4 DNA Repair 
The ability to detect and repair DNA damage is critical to the maintenance of cellular 
integrity. If normal cells cannot repair the damage, then they engage apoptosis to prevent 
the accumulation of cells with mutated DNA. Many chemotherapeutic agents cause cell 
death via DNA damage, but resistance is not always due to failure of the apoptotic 
pathway. Many tumor cells have increased capacity for DNA repair95 as well as increased 
tolerance of damaged DNA without engaging apoptosis96 . Increased tumor cell DNA 
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repair can be mediated through the Fanconi anemia (FA) pathway97 . Homology based 
DNA repair via this pathway involves the formation of a protein complex between FA 
proteins and. the breast cancer proteins (BRCA) 98 . The nonhomologous end-joining 
(NHEJ) DNA repair pathway, through the activity of DNA-dependent protein kinase 
(DNA-PK), is able to repair double strand breaks where sequence homology cannot be 
used to reform DNA6. Increased DNA-PK activity has been linked to acquired resistance 
to DNA damage99. The ability of tumor cells to continue to replicate DNA and proliferate 
even in the presence of DNA damage that would normally lead to cell cycle arrest or 
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Figure 2-1: The Hallmarks ofCancer 13 • Transformation of normal cells can lead to 
formation of cancerous cell populations. The hallmarks of a malignant 
tumor are evasion of apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, limitless replicative potential, invasion 
and metastasis and sustained angiogenesis. Recently, Hanahan and 
Weinberg revisited the hallmarks of cancer and added deregulated 
metabolism, DNA instability, evasion of immune system and chronic 
inflammation as hallmarks102. 
23 
A . 
8 18 8 8 18 1818(8 8 · 8 _~ 1 8 8 8 '8 _8 8 ; 8 818 8 8 
8 · normal epithelial 8 tumor-prone epithelial lntl,.tltlal ECM 
call cell I I I 
~ norm•l fibroblast I I I 
prot11aes \ lyayl oxidise (LOX) 
metastatic niche 
. neutrophil 
Figure 2-2: Illustration of cancer progression. A. Most cancer begins with a tumor-
prone epithelial cell. B. The resulting neoplasm recruits cancer associated 
fibroblasts (1), which then contribute to enzymatic remodeling of the 
ECM (2). This altered ECM creates downstream effects in the cell, which 
cause deregulated growth and hyperplasia (3). C. Once the tumor is large 
enough, it begins to recruit immune cells (4), which help in the subsequent 
sprouting of new blood vessels (5). The new vasculature is invaded by 
cancer cells that enter circulation (6). D. Circulating cancer cells remodel 
the ECM at a distant site, allowing invasion and colonization to occur (7). 
This new tumor then undergoes similar processes as the primary tumor, 
including more angiogenesis promotion (8). Taken from Lu et al.; 2012103 . 
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Figure 2-3: Mechanisms and Effecters of Chemoresistance. The normal life cycle of a 
chemotherapeutic agent can be disturbed by altered cellular processes that 
confer resistance. These processes include decreased drug influx, 
increased drug efflux, drug detoxification via chemical modification, 
better DNA repair mechanisms, and ignorance of pro-apoptotic signaling. 
These cellular behaviors are the result of alter genetic expression, which is 
heavily influenced by the ECM, cell-cell interactions and the 
microenvironment. From Fallica et al.; 2011 104• 
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Chapter 3: Cellular Microenvironment 
The extracellular matrix (ECM) is the scaffold on which most cells grow in vivo. The 
ECM has highly tunable composition and mechanical properties that can drastically 
affect cell behavior. Cells interact with the ECM directly through integrins, which bind 
specific amino acid sequences on certain ECM proteins105• The ECMs most basic 
function is as a platform for cell growth, but it also plays crucial roles in cell 
proliferation, differentiation and survival by providing biochemical and mechanical cues 
to the cells106•107• It is therefore not surprising that the ECM is a major player in disease 
progression, especially cancer107• In this chapter we will cover the composition of the 
ECM, its mechanical properties and its role in cancer cell fate. 
3.1 Composition 
The ECM is made up of proteins, glycosaminoglycans (GAGs) and water. The 
components are synthesized intracellular before being secreted where they join the 
existing ECM network. Protein components include collagen, elastin, fibronectin and 
laminin. Collagen is the most abundant protein in the human body, making up about 30% 
of all protein. There are over 20 types of collagen, but by far the most abundant is type I 
collagen108• The 3D gels used in this dissertation are made up entirely of type I collagen. 
Collagen serves two main functions, integrins binding and tensile strength. Collagen self 
assembles in fibers of 10-200nm width which can extend several hundred microns109• 
Elastin serves to confer elasticity to the ECM, allowing it to be deformed and return to its 
original shape. This is especially important for lung, blood vessel and skin tissue. 
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Fibronectin and laminin do not serve structural purposes, but promote cell-ECM 
interactions though integrins. 
GAGs, such as heparin sulfate, chondroitin sulfate, keratan sulfate, and hyaluronic 
acid are carbohydrate polymers that often associate with ECM proteins to form 
proteoglycans (with the exception ofhyaluronic acid). Proteoglycans are large, branching 
molecules with a net negative charge. This charge serves to attract sodium ions (Na+) 
which consequently attracts water. This keeps the ECM and the nearby cell hydrated. 
Hyaluronic acid (HA) also attracts water, but instead of performing a hydration functions, 
this water is used to resist compressive forces placed on ECM. Thus, HA is found 
abundantly in load-bearing joints. Another important consequence of this net negative 
charge is the ability of the ECM to sequester soluble growth factors to limit the 
bioavailability and diffusion distance. This is an incredibly important control on cell 
behavior, as the ECM can directly control biochemical signaling sensed by the cells103 . 
The specific structure and composition of the ECM depends on location and type 
of tissue. Epithelial ECM is organized into two distinct zones: the basal lamina and the 
stroma. The basal lamina, or basement membrane, is a 20-140nm thick membrane found 
directly beneath the single layer of epithelial cells110. It is a dense, tightly packed mesh 
consisting of collagen type IV, laminin glycoproteins, and heparin sulfate 
proteoglycans 111 . It serves a mainly structural function, although it is also involved in 
filtering nutrients, determining cell polarity and a barrier to foreign substances112• The 
stroma beneath the basal laminae is a mesh of loose connective tissue rich in collagen 
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types I and III. This network is maintained by resident fibroblasts. In bone, cartilage, 
tendons and ligaments this network is significantly denser and will have widely varying 
compositions. Bone ECM is mineralized and dehydrated to give rise to its extreme tensile 
strength. Bone is also maintained by specialized cell called osteoclasts and osteoblasts. 
Similarly, cartilage is maintained by specialized fibroblasts called chondrocytes. 
ECM composition and biochemical properties can directly affect cell behavior. 
Different tissues in the body contain different ECM proteins in different ratios, which 
associated cells are sensitive to. Cells express ECM-interacting proteins, with the most 
important and well studied being the integrins family of proteins. These heterodimeric, 
trans-membrane proteins are globally expressed in the body. Composed of an a- and ~­
subunit, of which there are dozens of varieties yielding hundreds of possible 
combinations, integrins can interact with specific ECM components with precise affinity 
and binding strength. The cytosolic domain of the integrins can then convert extracellular 
signals into intracellular protein cascades. 
In addition to direct cell-ECM contact, ECM proteins can bind specific signaling 
molecules released by nearby or distant cells, with release of these proteins being 
spatially and temporarily controlled. This level of precision is needed during 
development. ECM composition can change at very small length scales, which leads to 
pattern formation during embryogenesis 113• Vasculogenesis in developing organisms is 
predicated on endothelial cell migration and tubule formation, which is directed by 
certain ECM proteins114• ECM protein densities changes can lead to different mechanical 
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properties, which is another mechanism by which the ECM exerts an influence on cell 
behavior. Stiffer ECMs, which contain more growth factor proteins and integrin binding 
sites, are associated with increased cell proliferation and viability. Of particular interest to 
cancer, stiffer environments have also been associated with chemotherapy resistance and 
poor clinical prognosis. 
3.2 Mechanics 
The mechanical properties ofthe ECM are highly variable in vivo, and are based on the 
local ECM composition. The composition and emergent mechanical properties are 
informed by the needs ofthe particular tissue, and can vary over huge ranges. For 
example, ligaments and tendons need to have high elasticity but do not require much 
compressive resistance. Thus, these tissues are rich in elastin and are made up of 
amorphous, highly cross-linked ECM. Conversely, bone requires very little elasticity, but 
must bear extreme compressive forces. Bone ECM is therefore very rich in collagen, 
which are arraigned in parallel fibers based on the applied load's directionality. Brain 
tissue is devoid of most ECM proteins, leading to a very soft tissue, but is rich in 
proteoglycans and a special class of proteins called lecticans. This network is extremely 
well hydrated, possibly to resist the strong intracranial pressure (ICP). The interesting 
observation that brain tissue is resistant on-neuronal and glial tumor cell invasion leads to 
the possibility that the unique nature of the brain ECM is responsible for the brains 
resistance to metastases 115 . 
Recently, ECM mechanics has garnered a lot of attention for its role in 
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determining cell behavior. Matrix properties have been show to significantly impact a 
host of cell processes, including some of the most fundamental cell behaviors, with 
mechanics playing a particularly important role. Changes in cell morphology were one of 
the first observed responses of cell to growth on substrates with different stiffness. Stiffer 
substrates tend to have more adhesion sites for cells to attach to, leading to cell spreading 
and increased cross-sectional area116•117. Cell growth is also affected, with cultured cell 
reaching confluence faster when cultured on stiffer substrates. This effect is not solely 
due to increased spreading and cell size, but to an increased population of actively 
dividing cells118. Cell migration is also greatly affected by ECM stiffuess, not only do 
cells modulate speed based on substrate rigidity, they also selectively migrate up stiffness 
gradients119 and can even switch between different mechanisms ofmigration118•120•121 • 
These different mechanisms involve completely different adhesion proteins, secreted 
proteins and intracellular signaling pathways that can have numerous other downstream 
affects on the cell. More recently, the ability ofECM stiffness to direct differentiation 
fate has been observed122. Adult stem cells, in the presence of no other selective 
pressures, will differentiate into cell lines that natively exist in similar mechanical 
. th b 123 envuonments as e su strate . 
The observation that the ECM forms a bidirectional signaling cascade with local 
cells indicates that these cells must be sensing specific ECM properties. Not only do the 
cells detect the biochemical cues of specific ECM proteins, but the mechanical properties 
of the network as a whole also can inform cellular behavior. This is supported by the 
identification of cellular mechano-tranducers, which are able to turn ECM mechanical 
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properties into intracellular protein signals124' 125 . The cell cytoskeleton is anchored to the 
external ECM via focal adhesions, cellular structures containing large assemblies of 
macromolecules. These cell-matrix adhesions are where the most important mechano-
traducing protein, integrin, is found 126• The exact molecular mechanisms by which 
integrins senses mechanical cues remain elusive, but the process has been shown to be a 
key mediator ofbone resorption, vasculo- and angiogenesis, and cell cycle 
regulation 125•127. 
ECM stiffness also plays a key role in the diseased state. ECM stiffness is often 
increased in malignant tumors. This is the result of aberrant ECM regulation, which can 
result in increased collagen crosslinking mediated by lysyl oxidase (LOX), increased 
deposition of the Collagen I, II, III, V and IX, or decrease in elastin expression. Previous 
studies have shown that drug response is heavily influenced by ECM mechanics 128•129. In 
addition, patient survival rates can also be linked to the mechanical properties of the 
surrounding milieu, with a more rigid ECM correlating with poor prognosis107. That this 
is true is not surprising, given that clinicians often diagnose tumors based on increased 
local tissue stiffness130. This dissertation deals heavily with the ability ECM stiffness to 
direct cell behavior, including proliferation, migration, gene expression and drug 
resistance. The goal is to demonstrate the importance of tissue mechanics in tumor 
progression, so that it can be accounted for in developed 3D culture models. Evidence is 
mounting that in vitro systems that do no recapitulate the mechanics of native tumors will 
fail to produce clinically relevant results. 
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3.3 Relevance to Cancer 
Although not appreciated until recently, it is now known that the ECM plays a 
critical role in cancer development and progression. That this is true is not surprising, 
given that the ECM' s ability to direct cell behavior has been appreciated by 
developmental biologists for decades. The ECM is tightly controlled during 
organogenesis, and deregulation can have devastating results. These lessons have recently 
been applied to cancer development, and the ECM is now seen as a key mediator of the 
disease state. Many investigations have shown that ECM interacting proteins can be used 
as predictors of tumor behavior and patient outcomes131- 134, but few have looked at the 
composition and characteristics of the matrix itself despite indications from mathematical 
models that ECM density and homogeneity play critical roles in tumor 
development135•136. Although much work has been done, much of the ECM's role in 
cancer development remains a mystery. 
ECM stiffness appears to play a particularly important role in cancer 
development. The observation that tumors are stiffer than surrounding tissue is thousands 
of years old, with more recent studies showing that tumor stiffness correlates with poor 
patient outcomes in breast cancer137. As previously discussed, the stiffness of the ECM 
can affect cell migration, proliferation, morphology, apoptosis and protein 
expression138•139, all of which affect cancer cell fate. 
There are several characteristics of the ECM that lead to its important role in 
disease progression. Firstly, normal ECM is incredibly dynamic, with constant turrJover 
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mediated by associated cells. This process is heavily regulated, and a narrow balance 
between degradation and deposition must be maintained for normal function. Disruption 
of ECM control can occur through up- or down-regulation of a multitude of pathways, 
and this deregulation can be initiated by pre-cancerous cells, invasive, late stage cancer 
cells, or non-cancerous stromal cells. In addition the being susceptible to deregulation, 
ECM properties are highly interconnected, meaning a small, low-level change can 
propagate through the system resulting in large downstream affects. For example, the 
alteration in the deposition profile of ECM proteins can impact protein crosslinking via 
subtle changes in tertiary and quaternary structure. This will affect compressive and 
tensile strength of the matrix as a whole. Additionally, the altered protein interactions 
will affect the ability ofthe constituent proteins to bind and sequester soluble growth 
factors , which will be sensed by the cell. Even more directly, integrins binding site 
exposure can be impacted leading to alterations in cell-matrix interactions. Since the 
ECM and local cells participate in a mutual feedback look, any changes in cell behavior 
resulting from an altered ECM can lead to additional deregulation due to cellular protein 
expression. This is but one example of the interconnectedness of ECM properties, all of 
which inform each other as well as local cell behavior. Deregulation ofthis complex 
system can often lead to disease development and progression. 
3. 3.1 Effect on Cell Signaling 
Th~ hallmarks of cancer, as discussed previously, all lead to the malignant 
phenotype. The ECM can mediate and promote the development of many of these 
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hallmarks, both via direct biochemical interactions with cells or downstream cellular 
changes as a result of cell-matrix interactions. 
The ECM stores a large quantity of growth factors within its network, and release 
of the proteins is often tightly controlled. The ECM can also function as a spatially 
controlled growth factor sink to help shape concentration gradients. Additionally, ECM 
proteoglycans function as low-affinity co-receptors for growth factors 140' 141 and collagen-
integrin interactions142• Several ECM components also function as signaling precursors, 
which are released upon ECM degradation143• The ECM proteins mediating these 
interactions are often overexpressed in cancer, and can help the cells overcome their 
dependence on pro-survival signaling without the requirement of a mutated oncogenes or 
tumor suppressor gene. Similarly, the ECM plays a role in avoiding anti-growth 
signaling, either my sequestering the signaling molecules or by releasing competing 
molecules which overpower the antigrowth signal144. 
The ECM can also prevent cancer cells from undergoing apoptosis. This is 
mediated through increased cell-matrix adhesions, which are pro-survival and serve to 
suppress apoptotic signals 145• Increased ECM biding also prevents anoikis, a specific type 
of apoptosis resulting from the lack of cell adhesions105' 146• Increased ECM binding sites 
and matrix stiffness lead to increases in integrins and cadherin expression, which 
suppress pro-apoptotic proteins and can even induce growth factor expression by cancer 
cells129,147• This increased adhesion also allows cancer cells to congregate together, which 
is correlated with increased disease progression and decreased patient survival148• 
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3. 3. 2 The Angiogeneic Switch and the ECM 
Although the ECM is an important player in modulating survival and growth 
signaling cascades, it is even more important in the angiogeneic switch and the 
development of the invasive phenotype leading the metastasis. The ECM helps initiate 
angiogenesis by releasing pro-angiogenic factors including tumstatin and hexastatin, 
which are derivatives of collagen144. These protein fragments interact with VEGF to 
promote vascular branching from the existing vessel. Basement membrane ECM is 
initially present surrounding the existing vasculature, and must be degraded in order for 
angiogenesis to occur. This is another occurrence where increased MMP and other ECM 
cleaving enzymes perform pro-cancerous roles. After ECM clearance and vessel 
sprouting, invading endothelial cells require additional MMP-cleavage of the ECM149• 
Additionally, fibrillar collagen often seen in early tumor development increased 
endothelial cell invasion speed150. Endothelial cells would normally die if invading too 
far, but the ECM provides the cells with pro-survival growth factors, similar to its role in 
early cancer development151 . This prevents endothelial cell death and promotes 
neovascularization. Matrix mechanics also plays a key role, with increased ECM stiffness 
yielding faster moving endothelial cells152 and more vasculature branching153 . Finally, 
after vascularization, new basement membrane is deposited to stabilize the nascent 
vessels. Tumor-associated basement membrane is noticeably more porous than normal, 
leading to a leaky vasculature that allows for cancer cell extravasation and host immune 
cell invasion35 . 
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The role of host immune cells in a post-angiogeneic tumor is also of profound 
importance to cancer development as is mediated by ECM properties. Degraded ECM 
proteins serve as chemotractants for immune cells, which invade the tumor environment 
and initiate an inflammatory response103• Many of the pro-inflammatory cytokines are 
potent activators of cell growth, helping the tumor grow. Normally, immune cells would 
sense and arrest such growth, but dense, stiff ECM prevents T -cell and macrophage 
maturation, possibly due to polarization suppression154' 155 • This allows the tumor to reap 
the pro-growth benefits of the host immune response without having to fight the 
responsible cells. 
3. 3. 3 Role of ECM in Metastasis 
The observation that the ECM plays a critical role in cancer development at the primary 
site, leads to the hypothesis that it is also important in developing a metastatic niche. 
Successful metastasis requires not only extravasation from the primary site, but 
colonization and survival at a distant, non-cancerous site. Much of this process is 
stochastic, an example being cancer cells expressing different integrin isoforms 
successfully invading tissue where those isoforms are naturally found 156• However, there 
is mounting evidence that cancer cells remotely modify distant sites to generate a pro-
metastatic environment157. This process is thought to be mediated by hematopoietic 
progenitor cells, which are recruited and activated by the tumor and then proceed to 
change ECM composition at distant sites 158. There is also evidence that the distant site 
being remodeled is dependent on the expression of different ECM-interacting proteins. 
36 
MMP9 upregulation is thought to promote lung metastasis159, while CD44 has been 
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Figure 3-1: Normal ECM structure and Cell Interaction. Fibrillar collagen and 
branching, hydrophilic proteoglycans make up the bulk of the extracellular 
matrix. Collagen fibers bind to surface integrins on nearby cells, providing 
a direct link between the ECM and the cytoskeleton. 
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Mechanical Properties of the ECM. Beyond the biochemical cues of 
protein-protein interactions, the ECM effects cell behavior via mechanical 
cues. Cells are sensitive to single fiber strength and network stiffness, 
integrins binding strength a traction forces generation, and matrix 
degradability and pore size as barrier to migration. Taken from Griffith et 
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Figure 3-3: The ECM and Cancer Progression. The extracellular matrix plays a key 
role in regulating cancer cell behavior and driving disease progression. 
The ECM interacts with cancer cells as an anchorage site, migration 
barrier or guiding track, soluble protein signaling reservoir, low-affmity 
co-receptor, signal presenter, functional fragment and biomechanical 
force. Taken from Lu et al. ; 2012 103 . 
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Chapter 4: 3D Cell Culture 
The most important aim of any model system is that it can recapitulate the behavior of 
tumor cells in vivo in an arena that is easier to observe and study. In pursuit of this, 3D 
cell culture has become very popular over the last few decades. These culture systems 
sought to bridge the gap between 2D culture systems that were not reflective of in vivo 
conditions and costly, low throughput animal models. There are many 3D culture systems 
that have been developed, and a review of these will be presented in the next chapter. 
This dissertation uses 3D type 1 collagen gels as a 3D platform for cancer cell growth. 
These gels are cheap, tunable, scalable and easy to work with, allowing for high 
throughput assays160 . 
4.1 2D vs. 3D 
Some of the earliest models, that are still employed to this day, rely on cultures of tumor 
cell lines grown in monolayer. These systems are easy to maintain, easy to manipulate 
and give rapid and reproducible data. The vast majority of novel cancer therapeutics are 
screened for their efficacy against well-established cancer cell lines on high throughput, 
plate-based 2D systems104• However, in vivo tumor cells exist within a dynamic 3D 
environment that is not completely replicated by standard in vitro tissue culture 
techniques. 2D tissue culture plastic and 3D extracellular matrices (ECM), as scaffolds 
for cell growth, provide the cell with very different biochemical and mechanical 
environments. Cells growing in 3D matrices have mechano-transducers and ECM 
adhesion proteins globally expressed on their surfaces; however, cells grown in 2D only 
interact with a solid substrate on their basal surface 161. Culturing cells in 2D vs. 3D 
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platforms results in significant changes in cell growth162,1 63 , migration120,164, 
morphology147' 165, and gene expression161 '163 . Perhaps most importantly, cells grown in 
2D monolayer are almost alone ways less resistant to cytotoxic agents166. This is a 
significant drawback for these systems as drug efficacy in in vitro 2D systems is often not 
reflected by in vivo efficacy and resistance profiles 167. These differences contribute to the 
observation that 2D in vitro systems are poor indicators of in vivo processes 112,166,168. 3D 
systems therefore provide more clinically relevant results. 
4.1 .1 Mechanics 
As described above, the mechanical properties of the cellular microenvironment can 
drastically affect cell behavior, and this process is especially relevant to cancer. Not 
surprisingly, 2D cell culture does a poor job of recapitulating in vivo mechanical 
properties. Glass and tissue culture plastic are orders of magnitude less compliant than 
natural ECM, with the exception of mineralized bone. This leads to the formation of more 
stress fibers, and basal surface focal adhesion density is also markedly increased. 
Additionally, the focal adhesions formed in 2D culture are much more static, with less 
protein tumover169. This leads to a very different cell morphology and migration profile. 
Cells consistently move faster in 2D systems, due in part to the increased substrate 
rigidity73 , a trend that is also observed in 3D systems when rigidity is varied over 
biologically relevant ranges120. 
4.1.2 Polarity 
Beyond the affects of substrate compliance, simple geometry also plays a key role in 
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observed behavioral differences between 2D and 3D. The presence of an adhesive surface 
on only one side of the cell leads to an emergent, polarized phenotype, even in cell types 
that do not exhibit anisometric morphology normally138. Cells in 2D are much flatter, 
spreading out as much as possible over their substrate. In fact, cell spreading has been 
directly correlated with 2D substrate stiffness, with stiffer surfaces leading to increased 
cell cross-sectional area 131 • Cells in 3D can have either a spherical morphology or a 
highly branched, mesenchymal morphology, but rarely do they form flat, disc-like 
shapes 161,168. Beyond cell-substrate interactions, there are key differences in cell-cell 
interactions. In non-transformed cells, cells are restricted to one plane of growth, 
meaning cell-cell adhesions can only form in a ring around the cell. This configuration is 
typical of certain cell types in vivo, including epithelial cells, but it is not representative 
of most tissue types. Ad described is previous sections, cell-cell interactions are 
important determiners of cell behavior, including drug resistance. By restricting cellular 
crosstalk, 2D systems are unable to recapitulate this in vivo behavior. 
4.1.3 Nutrient/02 Gradients 
The need of cells in vivo to reside close to a capillary highlights the importance of 
nutrient delivery and waste removal in normal cell behavior. This function is often a rate-
limiting step in early cancer progression, and overcoming it is one of the hallmarks of the 
malignant phenotype 13 • Cells grown in 2D systems are not challenged to overcome this 
problem, as they are directly bathed in nutrient and oxygen containing media. Not only 
does this not create the struggle for nutrients observed in vivo, it also fails to promote a 
concentration gradient for nutrients and oxygen, and these gradients can inform cell 
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movement and persistence in vivo. Indeed, although migration speed increased in 2D, 
persistence decreases170. In fact, 2D migration can be approximated with a random-walk 






Figure 4-1: Morphology of2D and 3D culture cells. Cells in 2D exhibit polarized 
morphology, increased cross sectional area and stress fiber formation in 
the cytoskeleton. Conversely, cells in 3D are round and non-polar while 
not exhibiting any stress fibers. This is but one example of the drastic 
difference between 2D and 3D culture platforms. From Eke et al.; 2011 172• 
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Chapter 5: 3D Cancer Cell Culture in Experimental Systems 
From the above it seems clear that growing tumor cells in 3D is preferable when trying to 
model cancer accurately. Several 3D models of in vitro cancer growth have already been 
established, and these will be discussed below. These models take one of two forms: 
tumor spheroids or gel embedded cultures. The former involves growing tumor cells in 
suspension and allow them to self-organize into small clusters. These clusters can then be 
isolated until they grow to an appreciable size, at which point they can be used as 
surrogate tumors for experiments. Not all tumor cell types will form 3D cultures in this 
way, and in particular it is not applicable to cell types that normally grow in suspension. 
The second method involves seeding cells into a solution, which is then 
polymerized into a gel. The most commonly used substrates are collagen and Matrigel, 
but in theory a very wide range of substrates, both natural and synthetic, could be used. 
Cells in these 3D models behave more like native tumor cells and show increased drug 
resistance when compared to 2D culture systems. However one potential problem is that 
the increased drug resistance in 3D systems is attributed to cellular behavioral changes, 
when in reality it may also be affected by drug distribution. Cells that are part of the inner 
cell mass in these models are exposed to much lower drug concentrations than those 
experienced by the peripheral cells, and this may at least contribute to the relative drug 
resistance ofthese 3D cultures. 
Although no an in vitro system, the animal xenograft model also deserves to be 
mentioned. This method is designed to support the growth of tumors inside a real 
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biological system by injecting human cancer cells into an animal, usually a mouse, host. 
The mice used in this system have dramatic genetic alterations so that the injected cells 
are not immediately neutralized by the host immune system. The biggest practical 
drawback of this system is its cost and low-throughput, making the development of a 
better in vitro model all the more critical. 
5.1 Natural Scaffolds 
Naturally derived substances are attractive as 3D scaffolds for cell growth due to their 
biocompatibility and ability to faithfully mimic in vivo conditions. Four of the most 
commonly used naturally occurring scaffolds are Collagen, Matrigel Hyaluronic Acid 
and Silk. 
5.1.1 Collagen 
Collagen, as the most abundant naturally occurring ECM protein, is an obvious candidate 
as a 3D cell culture scaffold. It is biodegradable in its natural form, but the degradability 
can be reduced by induction of additional crosslinking between fibers. It contains natural 
cell and growth factor binding sites, allowing for normal cell attachment and migration. 
Additionally, collagen gels are easy to work with, as they self-polymerize at 
physiological pH and temperature. This allows cells to be embedded in the pre-gelation 
mixture without fear that the gelling process will harm them. Collagen content of these 
gels can be modulated over a wide range of concentration~, allowing for the study of gels 
with different stiffnesses, pore size and ligand density173. Optical properties of collagen 
gels allow for cellular imaging in real-time within the cells. The gel network is only 
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weakly scattering and does not fluoresce under normal conditions, allowing for relatively 
unimpeded confocal, bright-field or fluorescent imaging. The gels are also easily 
degraded using collagenase allowing for cell, protein and RNA/DNA recovery. 
Collagen gels have been used in both tissue engineering and cancer biology 
studies. In our lab, we have demonstrated that changing the collagen concentration of the 
gels will vary the gel stiffness over several order ofmagnitude174, and that this difference 
is enough to alter cell behavior175 . Our lab has also demonstrated that gel stiffness and 
ligand density can alter migration speed and modality121 . Other work has demonstrated 
that cell clusters grown in collagen gels will express pro-angiogeneic factors while 
forming tumor-like macrostructures176, showing the ability of these gels to promote in 
vivo like cell behavior. Collagen gels appear to be compatible with most cancer cell lines, 
having been used to grow breast177- 179, colon180--182, prostate174,1 83 '184, brain185- 187, and 
bone175, among many others. Collagen can also be used as a barrier for an MMP-
dependent invasion assay188, or as an injectable delivery vehicle for cells and proteins 189. 
5.1.2 Matrigel™ 
Matrigel is the trade name for a basement membrane protein mixture harvested from 
mouse sarcoma cells and sold by BD Biosciences. It is comprised mainly of laminin, 
collagen IV, and heparin sulfate, with additional components including growth factors 
and proteases190. Since the protein mixture is derived from naturally occurring tumors, 
the composition is more mimetic of a natural tumor ECM than any other system. Like 
collagen, it is biodegradable, and promotes cell and growth factor attachments and is non-
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immunogenic. Gelation is induced similarly to collagen, with the scaffold self-assembling 
at physiological conditions. Unlike collagen, the growth factors are incorporated into the 
mixture from the start, and do not require cell synthesis. Matrigel promotes in vivo-like 
cell morphology and migration. The main drawback to Matrigel is due to it being a 
proprietary product, so the exact components are unknown to end-users. Additionally, 
there have been reported problem with batch-to-batch heterogeneity191 . 
Matrigel is the most commonly used 3D scaffold for cell based cancer assays, 
mostly due to its availability as a commercial product as for its ability to induce cancer 
cell migration, invasion and proliferation. One of the most common uses of Matrigel is as 
a scaffold for a cancer cell invasion assay. Since Matrigel is derived from a basement 
membrane, it approximates the environment that metastatic cancer cells must penetrate in 
order to enter circulation. The most common experimental setup involves a layer of 
Matrigel on top of a porous scaffold. Chemotractants can be incorporated beneath the 
scaffold, while cells are added on top of the Matrigel. Counting the number of cells that 
migrate through the Matrigel and into the lower chamber has been used extensively as a 
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Matrigel. In one study, cells shown to have similar growth kinetics in 2D showed very 
different growth patterns in 3D Matrigel scaffolds, with the more invasive cell type 
forming extensively branched, mobile structures194. Matrigel has also been shown to 
increase tumor growth when injected with exogenous cancer cells into a mouse host195 . 
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5.1. 3 Hyaluronic Acid 
As previously discussed, Hyaluronic Acid (HA) is a naturally occurring GAG found in 
the ECM that is involved in water retention for compressive strength. It is biodegradable, 
non-immunogenic and easily obtained. Naturally occurring HA receptors allows cells to 
directly interact with the scaffold fibers, although the resulting attachments are 
comparatively weak. Scaffolds can be created using a variety of fabrication techniques, 
including phase separation, solid freeform printing, electro-spinning or micro-patterning. 
This allows for tunable properties including geometry, pore size, stiffness and 
crosslinking. Drawbacks of HA include lack of mechanical integrity and instability in 
solution196• To overcome these weaknesses, HA is usually incorporated into a gel with 
another natural component, usually gelatin197, fibronectin198 or collagen199• 
Hyaluronic acid gels have been used as 3D cancer models for drug development 
and testing. When compared to cells grown in 2D, HA gels supported cells with increased 
resistance to the cytotxic drug camptothecin, docetaxel and rapamycin200 as well as 
doxorubicin and 5-fluorouracie01 . This is especially important, as HA has been shown to 
activate pathways associated with drug resistance in vivo202 . This indicates that the 
increased drug resistance of these cells is due to a biochemical change instead of just a 
dimensional of mass transport difference. This means that HA gels could be useful both 
as a structural scaffold for cell growth, but as a chemically active player in cancer cell 
behavior. This would provide a more rigorous drug-testing platform for initial studies 
into drug efficacy. 
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5.1.4 Silk 
Silk is a naturally occurring polymer that is harvested from the Bombyx mori silkworm 
cocoon. It is lightweight and elastic, while possessing the highest tensile strength of any 
naturally occurring fiber, comparable to that ofKevlar 49. It is only mildly immunogenic 
and promotes cell attachment. There are hosts of processing technologies that allow the 
silk to be delivered as a mesh, fiber, sponge or membrane, yielding a wide variety of 
potential uses. Downsides of silk include difficulty in isolating the protein and low 
biodegradability203 . 
Although silk gels have been used extensively as biomaterial for tissue 
engineering204, they have received relatively little use as a scaffold for in vitro tumor 
growth. Initial studies have shown that 3D silk gels promote angiogeneic protein 
expression in osteosarcoma cells comparable to that found in vivo, but substantially 
different from 2D culture systems205 . Breast and prostate cancer cells have also been 
grown on these gels, resulting in increased MMP-9 expression corresponding with 
increased invasiveness and migration speed206. These studies suggest that silk could 
potentially be a valuable biomaterial for cancer drug discover and basic cancer biology 
research. 
5.2 Synthetic Scaffolds 
With recent advances in materials science, biomaterials and industrial chemical 
manufacturing and synthesis, synthetic scaffolds have caught up to harvested natural 
materials on cost and availability. These substrates have the advantage of being 
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homogenous and well characterized, allowing for greater control of relevant mechanical, 
chemical and structural properties than is possible with naturally derived scaffolds. 
5.2.1 Polyethylene Glycol 
Polyethylene glycol (PEG) is a polyether that is the most widely used synthetic 
biopolymer. Its attractiveness as a biopolymer comes from the widely differing 
geometries PEG can be synthesized with. Single polymer chains can have highly 
branched structures, yielding a highly crosslinked mesh after gel formation. This network 
resembles that of natural ECM. PEG is highly hydrophilic, meaning proteins will not 
attach to it. This means that it is not immunogenic, but it also promotes no cell 
attachment and actively resists protein and cell penetration. Because of this, PEG gels are 
engineered to have hydrophobic domains. Additionally PEG gels can be chemically alters 
to include periodic peptide domains coding integrin binding sites207 and MMP 
degradation sites208 . This yields a system with tunable physical properties from gelation 
and conditions as well as tunable chemical properties from peptide addition. 
5.2.2 PCLIPLGAIPVA 
Chapter 1: Although chemically different, polycaprolactone (PCL), poly(lactic-co-
glycolic acid) (PLGA) and polyvinyl alcohol have similar properties and uses. All are 
hydrophobic polymers of small subunits, which can be of varying lengths. All are hie-
inert and biodegradable. PLGA and PCL have been improved by the FDA for use in 
implantable devices. As with most synthetic fibers, they have stronger tensile strength 
than naturally occurring fibers like collagen, but are unable to promote cell attachment 
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natively. Scaffolds can be synthesized by a number of methods, including electrospinning 
photocrosslinking and sol-gel synthesis209- 211 . 
5.2.3 Polystyrene 
Polystyrene (PS) is a synthetic aromatic polymer that is one of the most widely used 
plastics in the world, with several billion kilograms produced every year. It has been 
used in 2D cell culture systems for decades, but has recently been commercialized as a 
porous 3D scaffold for cell growth. Gels can be synthesized using standard 3D printing 
techniques, or standard sol-gel synthesis. The system is incredibly cheap, only mildly 
immunogenic and promotes cell attachment similar to tissue culture plastic212 . 
5.3 Spheroids 
The oldest method of 3D cell culture, cancer spheroids have been around since the 1970s. 
These systems do not require advanced materials, like in synthetic scaffolds, or harvested 
proteins/GAGs, which were expensive and had major impurity issues 40 years ago. 
Methods of creating spheroid utilized cheap, easy to acquire polymers (agarose ), existing 
cell culture plates (hanging drop) or laboratory glassware and a motor (spinner flasks). 
Today, more sophisticated protocols exist, but the vast majority of spheroids are created 
using 40-year-old methodologies. 
5. 3.1 Agarose 
Agarose is a polysaccharide polymer extracted from seaweed, which is widely available 
for low cost. It comes as white powder that dissolves in near boiling water, and then 
forms a gel when cooled. Its most well known use is in gel electrophoresis, where its low 
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affinity for biological molecules and large pore size make it ideal for size separation 
protocols. Modifications of side groups are well established, allowing for tightly 
controlled gel properties including strength, stiffness and pore size. 
The ability of cancer cells to grow on non-adherent surfaces has been known for 
several decades. Because only cancer cells show anchorage-independent growth, growth 
assay on soft agar (of which agarose is the major component) was and is still used to 
diagnose the malignant neoplastic transformation213 . With the development of agarose 
scaffolds as a diagnostic technique came the use of these gels to promote in vitro 
spheroid formation214 . When placed in a glass well, agarose forms a conical well 
structure that presents no adhesion sites for cells. This funnels cells to the low point in the 
cone, where they spontaneously interact and form large cell masses. This technique is 
cheap, easy and high throughput. 
5.3.2 Hanging Drop 
The hanging drop method of inducing cell aggregation has been around since the 
beginning ofthe previous centuri15 . The basic idea behind the method is to keep cells in 
suspension, without giving them a surface to settle on to due to gravity. This is achieved 
by hanging a drop of suspended cells upside down from a surface and allowing them to 
self aggregate. The major limitation of this system is volume, as large drops cannot stay 
stably hanging without support. As a result of small volume droplets (1 Os of Ill), 
evaporation is a major challenge, as the loss of only a few microliters of water can 
drastically change the osmolarity of the media to toxic levels. Conversely, the small 
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volume allows this protocol to be applied to 384 well-plates, making it extremely 
efficient and high throughput. 
This technique has been used extensively in cancer research. Hanging drop brain 
tumors have been formed, and shown to retain their invasive and proliferative 
phenotype216. This method has also been used to grow many other cancer cell lines. 
Recent advancements in the method have used a small hole above the drop as an inlet for 
additional media and drug to the system. This study also used a water reservoir beneath 
the drops to counter evaporation. The resulting spheroids showed the decreased drug 
sensitivity that is commonly observed in large cancer cell masses217 . 
5.3.3 Spinner Flask 
Spinner flasks are a suspension based culturing system that is often used for continuous 
cell passaging. In this system, a suspension of cells is continuously stirred inside a sterile 
flask. Gas exchange is promoted via an inlet and outlet port on the flask, with the stirrer 
serving to agitate and aerate the cell suspension. Passaging cell in this system is 
significantly easier than standard adherent culture systems, as cell-containing-media can 
be removed and replaced with fresh media to reduce the cell density and promote further 
growth. 
In certain cancer cell lines, this type of growth is suspension allows the cells to 
interact with each other and form clusters. Some drawbacks of this system are the time it 
takes to form the spheroids and heterogeneity within the spheroids. Spheroid formation 
protocols involving spinning flasks often take 30 days before spheroid harvest. This is 
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quite slow in comparison to the turnaround of other protocols. Additionally, the resulting 
spheroids have a wide range of sizes. Filtration may be used to set a size minimum, but 
spheroid number becomes the limiting factor if too-large a filtration size is used. 
5.4 Xenograft Animal Model 
Another commonly used platform for cancer drug screening 1s the mouse 
xenograft model. This method involves injecting human cancer cells into a severe 
combined immunodeficient(SCID) mouse, usually subcutaneously. These cells will form 
a palpable tumor within a few weeks, and the effectiveness of anti-cancer drugs can be 
evaluated against these tumor bearing mice218 . There are a number of problems with this 
model, which combine to make this method unattractive for studying chemoresistance. 
Firstly, there are interspecies differences between mice and humans that can affect drug 
metabolism, drug delivery, drug toxicity and the natural history of the implanted tumor. 
In order for the mice to accommodate human tumor cell xenografts they must be 
profoundly immunodeficient. This lack of a functional immune system has two 
consequences: it makes testing immunomodulatory strategies impossible and it removes 
any role of the immune system in the efficacy of anti-cancer agents. The SCID mouse 
model may also underestimate the normal tissue toxicity of DNA-damaging strategies, as 
SCID mice have defective DNA repair pathways219 . 
Perhaps the most important shortcoming of this model is its failure to recapitulate 
the complex and heterogeneous cellular and extracellular matrix components of a tumor. 
The injected cells are all identical, leading to a relatively homogenous tumor mass, unlike 
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a real tumor where there is likely to be considerable heterogeneity between tumor cells. 
Additionally, these tumor cells are unable to interact with human stromal cells, which is 
an important characteristic of normal tumors. This problem is exacerbated by the fact that 
relatively few human cancer cell lines are usually used in xenograft models, thus failing 
to represent the vast range of genetic and epigenetic variations found in human cancers. 
These xenograft models are labor and animal intensive and not suited for high throughput 
assays, so concessions must be made on the number of cell lines that can be tested. 
Although prudent for cost and speed considerations, this often means that drugs with 
minimal efficacy in humans will show activity in mouse models220 . 
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Figure 5-l: Monomer structures of polyvinyl alcohol (PVA), polycaprolactone (PCL), 
polystyrene (PS), poly (lactic-co-glycolic acid) (PLGA), and polyethylene 














Figure 5-2: Schematic overview of the hanging drop method. The lid of a 384-well 
plate is modified to contain a 1.6mm hole above the center of every well. 
15ul of cell suspension is pipette through the hole, and the pipette tip is 
removed causing the drop to stick to the plate cover. The hole allows for 
subsequent addition of more media or experimental treatment. The result 
is a cell spheroid that is kept at the bottom of the well by surface tension 
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Figure S-3: Schematic overview of the spinner flask protocol. Cells are lifted from 
normal2D culture conditions, diluted in media and added to the spinner 
flask. This protocol is suitable for normal cell passaging, embryoid body 
growth and cancer spheroid. As labeled in the figure, cancer spheroid 
development takes significantly longer. Figure taken from Wartenberg et 
al. 2001 221 • 
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Chapter 6: Alteration of Cellular Behavior by Culture in 3D Collagen 
Gels 
Most investigations into cancer cell drug response are performed with cells cultured on 
flat (2D) tissue culture plastic. Emerging research has shown that the presence of a three-
dimensional (3D) extracellular matrix (ECM) is critical for normal cell behavior. Despite 
this realization, the exact nature of the ECM' s effect on cell behavior is poorly 
understood. To address this knowledge gap, cell behavior between 2D and different 3D 
conditions was investigated, employing real-time, live cell tracking to directly observe 
U20S human osteosarcoma and MCF7 human adenocarcinoma cells embedded in type 1 
collagen gels. The collagen content of the gels was altered, to expose the cells to different 
mechanical and biochemical environments in 3D. The activation of the important PI3K 
signaling pathway under these different growth conditions was studied, and the response 
to inhibition of both PI3K and mTOR with PI103 investigated. Both cell lines grown in 
3D gels show reduced proliferation and migration as well as reduced PI3K pathway 
activation when compared to cells grown in 2D. MCF7 cells also showed reduced drug 
sensitivity in 3D conditions, and this resistance was affected by gel properties. 
Conversely, U20S cells showed both an increase and decrease in PI-103 sensitivity, with 
the alteration being dependent on gel conditions. These behavioral changes were also 
reflected in altered protein expression as probed by western blot. Thus a collagen ECM 
can protect MCF7 and U20S cells from PI-103, but this effect is not a straightforward 
one. This data suggest that 3D gels may provide a better medium for investigation of anti-
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cancer drugs than 2D monolayers, but that further study is needed to determine which 3D 
models are the most realistic. 
6.1 Introduction 
Over the last 40 years, 5 year survival rates for cancer patients have risen dramatically, 
but total death rates have remained stubbornly high222 . This reflects both our ability to 
effectively fight primary tumors and our inability to treat secondary or recurring lesions. 
This clinical failure is mainly due to persistent tumors which arise from resistant 
populations of cancer cells223'224. The molecular mechanisms of chemoresistance have 
been extensively studied56'76'90'225 '226 ; however this has not translated into clinical success. 
The gene expression profile of tumor cells changes after treatment227- 229, leading to a 
more drug-resistant cell population. This resistant phenotype is initially present in the 
tumor and is enriched during chemotherapy indicating clonal expansion of the resistant 
individuals229 . The ability to understand and predict the characteristics of the resistant 
cells will help increase our ability to treat chemoresistant tumors. 
The phosphatide inositol 3 kinase (PI3K)/ AKT pathway is an important 
intracellular signaling cascade which effects cell growth, migration, protein expression 
and survivat230. Figure 6-1 shows a simplified version of the signaling pathway. Elevated 
PI3K activity is observed in many cancers; either due to a constitutively active PI3K 
mutant or a loss-of-function PTEN mutant, leading to aggressive cell growth and 
invasion230 . Several pathway proteins, including PI3K itself and the mammalian target of 
rapamycin (mTOR) have been investigated as potential targets for new anti-cancer 
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drugs231 . mTOR is a cellular kinase that is found in two distinct complexes232 . Both 
complexes integrate sensors of nutrient and energy levels and regulate downstream cell 
functions. Increased mTOR Complex 1 (mTORCl) activity results in higher global 
protein expression, and inappropriate levels of activity have been linked to several kinds 
of cancer233 . Phosphorylation of ribosomal protein S6 (pS6) is a downstream indicator of 
mTORC1 activiti34, whilst phosphorylation of the proline-rich Akt Substrate (PRAS) is 
an upstream indicator of mTORC 1 activity, with PRAS acting to inhibit mTORC 1235 . 
mTOR Complex 2 (mTORC2) regulates cytoskeletal organization and turnover as well as 
AKT phosphorylation. Increased mTORC2 activity leads to the formation of stress fibers 
and increased cell mobiliti36. Phosphorylation of AKT (pAKT) is a downstream 
indicator ofmTORC2 activitr37 • To help understand and quantify the effects of the 
tumor ECM on cell behavior, we have compared proliferation, migration and protein 
expression ofU20S osteosarcoma cells between 2D and 3D collagen gels, and 
investigated the effect of changes in the ECM on inhibition of the PI3K pathway. 
6.2 Materials and Methods 
6. 2.1 Cell Culture 
Experiments were performed on the pediatric osteosarcoma cell line U20S or breast 
adenocarcinoma cell line MCF7 (ATCC, Manassas, VA). Cells were cultured in 
complete RPMI media supplemented with 1 0% fetal calf serum and 1% penicillin-
streptomycin solution (10,000 IU/ml penicillin; 10,000 f.lg/ml streptomycin). Cell 
cultures were maintained in 2D monolayers in a humidified incubator at 37°C, 5% C02. 
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PI-103238, a PI3K and mTOR inhibitor was purchased from Cayman Chemical (Ann 
Arbor, MI). 
6. 2. 2 Collagen Matrix Preparation 
Collagen Type 1 gels were prepared as described previously160. Briefly, Collagen Type 1 
stock solution (BD Biosciences, San Jose, CA) was diluted to 8.5mg/rnl using 0.02N 
Acetic Acid. This solution was diluted to the experimental collagen concentration (3 or 4 
mg/ml) by mixing equal volumes of collagen stock solution and neutralizing buffer 
(lOOmM Hepes in 2x PBS, pH 7.3) with PBS. 100fll ofthe collagen solution was pipetted 
into a 96 well plate (MatTek, Ashland, MA) then placed in an incubator (37°C, 5% C02) 
for 2 hours to allow for complete polymerization. The polymerization time was kept 
consistent as previous experiments indicated that polymerization time can significantly 
affect pore size (unpublished data). After polymerization, 100fll of media was added on 
top of the gels. 
6. 2. 3 Cell Tracking Experiments 
For cell culture experiments, cells stained with Sf.!M CMRA (Molecular Probes) were 
added to the unpolymerized collagen solution to a final concentration of 100,000 cells/ml 
for the proliferation assay and 30,000 cells/ml for migration trials. The gels were then 
polymerized as described above, resulting in cell-embedded collagen gels. Media was 
replaced with fresh media daily. When applicable, experiments were exposed to 250nM 
ofPI-103. For these experiments, PI-103 was added to the collagen solutions and the 
quenching media. Additional drug was added with each subsequent media change to 
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maintain the initial drug concentration. 
Images were acquired using a DMI600B microscope (Leica, Solms, Germany) 
and ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) using a 
spinning disc confocal setup (Yokogawa, Tokyo, Japan). Imaging was done using Micro-
Manager 1.4 Software (http://www.micro-manager.org). Confocal images were analyzed 
using !MARIS 7.3.2 (Bitplane Inc., St. Paul, MN). Cells were analyzed using the spot 
tracking and surface detection routines. Spot tracking gives the centroid position of each 
cell at each time point and was used to track cell number and cell movement over time. 
Surface detection outlined the 3D surface of each cell, and was used for cell size and 
shape measurements. Cell size was used as an excluding measurement to reject overly 
small cells from being included in cell number and cell movement measurements. 
6.2.4 Western Blot 
Cells cultured in 3D collagen were released from collagen gels by incubation with 
collagenase (lOOU/mg/ml, Gibco) at 37°C for one hour. Cells harvested from standard 
tissue culture plastic were also treated with collagenase to ensure this treatment did not 
affect our results. Liberated cell suspensions were normalized by cell count and lysed in 
lysis buffer (lOmM Tris, lOmM NaCl, lmM EDTA, 1% v/v triton xlOO, 10% v/v 
glycerol, 0.01% w/v SDS, 0.05% w/v deoxycholate, buffered to pH 7.4) for 15 minutes 
on ice and centrifuged for 10 min at 15,000xg. Whole celllysates were then subjected to 
10% SDS-PAGE followed by electrotransfer onto PVDF membranes. Membranes were 
blocked overnight at 4°C in 5% non-fat dry milk (BioRad) in Tris buffered saline with 
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0.1% Tween-20 (TBST, 20mM Tris pH 7.6, 135mM NaCl) before primary antibody 
incubation in 0.5% non-fat dry milk in TBST (Santa Cruz) for one hour at room 
temperature. After washing in TBST, membranes were incubated in secondary 
(horseradish-peroxidase conjugated) antibodies (AbCam) in TBST for one hour at room 
temperature. Membranes were visualized with Pierce ECL substrate (Thermo 
Scientific). All protein bands were normalized to GAPDH content and analyzed via 
densitometry using ImageJ. 
6.3 Results 
In order to investigate the effects of the ECM on cell behavior the proliferation, 
migration, protein expression and response to PI3K inhibition ofU20S and MCF7 cells 
on tissue culture plastic and in Type 1 collagen gels of different collagen concentrations 
was investigated. U20S cells were chosen due to their high native PI3K/ Akt pathway 
activitl39, giving us an attractive drug target. Additionally, U20S cells grow well in our 
collagen gels and on tissue culture plastic, making them very easy to work with. MCF7 
cells were chosen due to their wide use in in vitro experiments. The cells are also very 
robust and react well to being embedded in collagen gels. 
Because the 3D culture conditions introduce inherent differences in local cell density, the 
growth of cells seeded at different densities within collagen gels was analyzed. As can be 
seen in Figure 6-2 a 100 fold variation in the initial seeding density, from 3,000 to 
300,000 cells/ml has no effect on the proliferation ofU20S cells in 3D gels containing 
3mg/ml collagen over a 96 hour time course; at each seeding density the U20S cells 
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roughly double over the 96 hours of the experiment. Thus over this range of cell densities 
there is no effect of seeding density on the growth ofU20S cells in 3D collagen matrices. 
Similar results were obtained for the MCF7 cell line (data not shown). A seeding density 
of 100,000 cells/ml was chosen for subsequent 3D samples. For experiments in 2D, the 
seeding density was chosen so that cells would not reach confluence prior to the end of 
the experiment. U20S and MCF7 cells become confluent at approximately 30,000 
cells/cm2, and were therefore seeded at 1000 cells/cm2. 
Next, the effect of the live cell dye on the proliferation ofU20S and MCF7 cells 
in 3D collagen gels was investigated. The CMRA fluorophore has been used previously 
without effect on cell behavior 240, but this was not in 3D culture conditions. U20S cells 
grown in 3mg/ml collagen type 1 gels were stained with O)..LM, 2)..LM or 5)..LM CMRA and 
cell number was monitored over 96h. Figure 6-3 shows that CMRA did not affect cell 
proliferation in 3mg/ml type I collagen gels. The same control was performed on MCF7 
cells, which showed a similar insensitivity to the presence of CMRA. Differences in the 
behavior ofU20S and MCF7 cells between 2D and 3D culture conditions cannot be due 
to the inclusion of the dye. 
6. 3.1 Presence of a 3D ECM Affects Cell Behavior 
The proliferation ofU20S and MCF7 cells was examined in type I collagen gels of 
varying densities. U20S cells proliferated significantly slower in 3D collagen gels than in 
2D monolayer (Figure 6-4). Cells grown as 2D monolayers on tissue culture plastic had 
doubling time of24-30 hours, whilst cells grown in either 3mg/ml or 4mg/ml type I 
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collagen gels only doubled once over the 96 hour experiment. Similar results were 
observed in MCF7 cells (Figure 6-5), although MCF7 cells grew slower in 2D and faster 
in 3D compared to U20S cells. 
Next the migration speeds ofU20S cells in 3D collagen gels and on tissue culture plastic 
were compared. U20S cells moved significantly faster on 2D tissue culture plastic than 
in either 3mg/ml or 4mg/ml type I collagen gels (51-!m/hr in 2D compared to 2!-!mlhr in 
3D; p < 10-5) (Figure 6-6) This is consistent with previous studies, which have shown 
that migration speed of cancer cells121 and fibroblasts 104 is severely inhibited in 3D 
conditions. The same experiment was attempted on MCF7 cells, but these cells showed 
negligible(< 500nm/hr) movement in 3D. This also made subsequent investigations into 
the effect ofPI103 on MCF7 cell migration unnecessary since there is no movement for 
the drug to inhibit. 
This evaluation of the proliferation and migration ofU20S and MCF7 cells clearly 
shows that these cells behave very differently in 3D collagen gels than on flat 2D 
substrates. Because the PI3K pathway is critical to multiple cellular processes, the levels 
of key proteins in the PI3K/Akt pathway were compared between U20S cells grown in 
2D and 3D (Figure 6-7). U20S cells growing in both 3mg/ml and 4mg/ml type I 
collagen gels showed considerably lower levels of phosphoS6 and phosphoPRAS than 
when grown in 2D monolayer, and these differences were far greater than any differences 
observed in levels oftotal S6 and total PRAS between these conditions. PhosphoAkt 
(pAkt) was undetectable in cells grown in 3D despite there being more total Akt in U20S 
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cells grown in 3mg/ml and 4mg/ml type I collagen gels than in 2D monolayer. Overall 
the reduction in levels of these phosphorylated proteins in U20S cells growing in 3mg/ml 
and 4mg/ml type I collagen gels strongly suggest that the PBK/mTOR pathway is much 
less active under these conditions, which would be in keeping with the observed 
reduction in cellular proliferation and motility in 3D gels. 
6. 3. 2 Collagen Content and Dimensionality Affect Efficacy of P II 03 Treatment 
Culturing U20S and MCF7 cells in 3D collagen gels produces very different behavior 
than on standard tissue culture plastic. Further, in U20S cells the move to a 3D culture 
platform yields very different levels of activity in the important PBKIMTOR pathway. 
How does this difference in behavior and PBK pathway activation affect the response of 
U20S cells to pharmacological inhibition of the PI3K/mTOR pathway? As can be seen 
from Figure 6-8, the response ofU20S cells to the pan PBK and mTOR inhibitor PI103 
is more complex than the differences in cell behavior and PBK pathway activation might 
suggest. The proliferation of U20S cells growing as a 2D monolayer is clearly reduced 
by Pll 03 such that by day 8 oftreatment there are only 50% as many cells present as in 
the untreated control. However, although the effect ofPI103 on cell number is less on 
U20S cells growing in 4mg/ml type I collagen gels, as would be anticipated from their 
reduced proliferation and reduced pathway activity, the response of U20S cells growing 
in 3mg/ml type I collagen gels is very different. Despite there being no appreciable 
difference in the activation status ofthe PI3K pathway between U20S cells grown in 
3mg/ml and 4mg/ml type I collagen gels (Figure 6-7), in U20S cells growing in 3mg/ml 
type I collagen, PBK pathway inhibition by PI103 produces a significantly greater 
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reduction in proliferation than in either 2D or 4mg/ml type I collagen; after 8 days of 
treatment there are only 40% as many cells as in the untreated controls. 
We performed the same experiment on MCF7 cells to show that these results can be 
obtained from multiple cell lines (Figure 6-9). After 8 days, cells in 3D (both 3mg/ml 
and 4mg/ml gels) showed very similar survival, whereas cells in 2D were significantly 
more sensitive to the anti-proliferative effects ofPI103. Interestingly, at early time points 
there was a significant difference between the 3D samples, but this discrepancy was gone 
after 8 days. We plan on exploring protein expression in MCF7 cells in these conditions 
in future studies. 
Given the reduction in motility in U20S cells grown in type I collagen gels in 
comparison with that in 2D monolayer the effect of PI3K pathway inhibition on cellular 
motility in these different conditions was also investigated. As can be seen in Figure 
6-10, U20S cells growing in 2D monolayers are significantly less motile after treatment 
with Pll 03 than when untreated, and there is no effect of Pll 03 on the motility of U20S 
cells growing in 4mg/ml type I collagen gels. However U20S cells growing in 3mg/ml 
collagen gels showed significant reduction in motility after treatment with PI103. Under 
these conditions there was a 39% reduction in cell speed after Pll 03 treatment in 
comparison with a 24% reduction in cell speed in U20S cells growing in 2D monolayer. 
Thus not only does culturing U20S cells in 3D collagen gels have significant effects 
upon their proliferation and motility, and significantly reduce the activation of the PI3K 
pathway, but it also alters the way in which these cells respond to pharmacological 
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inhibition of this pathway. However the situation is more complex as the concentration of 
collagen within the gel also has a significant effect on the response of U20S cells to 
PI3K pathway inhibition. 
6.3.3 PI103 Reduces Expression ofPI3Kpathway proteins in 2D and 3D 
In an attempt to explain the observed difference in drug sensitivity between the 
two different collagen concentrations the effect of Pll 03 treatment on the levels of 
various phosphoproteins in the PI3K pathway was assessed. As can be seen from Figure 
6-11, Pll 03 treatment reduces levels of pAkt to undetectable in U20S cells growing in 
2D monolayer. There is no appreciable effect of Pll 03 on levels of phospoPRAS in either 
2D or 3D conditions. Pll 03 reduces levels of pS6 in both 2D and both 3D conditions. 
Thus there is no clear difference in PI3K pathway phosphoprotein responses to Pll 03 
between U20S cells growing in 3mg/ml type I collagen gels and those growing in 
4mg/ml collagen gels, despite the very clear differences in anti-proliferative and anti-
motility effects of this agent under these two conditions. 
6.4 Discussion 
Our study provides quantitative understanding of the role of ECM in altering 
cellular behavior, in particular the response ofPI3K pathway, in 2D and 3D 
environments. Our data indicates that the presence of a three-dimensional ECM 
significantly affects the proliferation and motility ofU20S and MCF7 cells and is 
consistent with emerging research into the role ofECM in cell behavior 174. This study, 
along with several others112•162•173•241 •242, indicates that the 2D cell culture paradigm is 
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limited in its capacity to provide detailed understanding of cellular behavior and that the 
incorporation of 3D culture techniques would be of considerable benefit for a 
comprehensive understanding of cellular behavior. Type 1 collagen gels are an attractive 
platform for future in vitro investigations of cell behavior. The gels are easy to create, 
inexpensive and are conducive to live cell manipulation and imaging. The gels are also 
customizable, with the ability to control pore size, ligand density and stiffness by either 
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compounds to alter the gel structure 173'243 . All of these ECM characteristics are tightly 
controlled in vivo and can contribute to many kinds of pathologies. 
Our study demonstrates that the presence of a 3D ECM is sufficient to alter the activation 
of the PI3K/Akt pathway in U20S cells: This reduced activation was consistent with an 
observed reduction in cellular proliferation and migration speed in cells growing in 3D 
matrix. Future investigations are needed to understand how a mechano-chemical signal 
from the ECM is transduced to intracellular signaling cascades. 
Previous work has shown that the presence of ECM proteins is sufficient to confer 
resistance to cancer cells against anti-tumor agents 244 • Our data supports this observation, 
but also shows that the drug response is affected by ECM properties including 
mechanical stiffuess and protein content. Higher collagen concentrations resulted in a 
more resistant population in U20S cells, which is in agreement with the observation that 
increased collagen 1 content in certain tumors is associated with poor patient survival 107. 
Further study is needed to understand why the stiffer gels conferred a selective advantage 
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to the U20S cells. One hypothesis is that the cells in 4mg/ml gels were able to activate an 
alternate survival pathway in order to circumvent the drug' s inhibition of key PBK/Akt 
pathway proteins. A likely candidate for this alternative pathway is the MAPK 
pathwa/45- 248 . In MCF7 cells, the presence of a 3D collagen matrix was sufficient to 
confer a resistance to the anti-proliferative effect ofPI103. Although it appears the 
collagen content of these gels may have a role in how these cells respond to drug over 
time, at the end of our 8 days experiment there was no significant difference between 
cells in gels with different collagen content. We did see a significant difference between 
MCF7 cell in 2D and 3D, further highlighting the potential use of 3D culture techniques 
as a more biomimetic drug validation platform. 
The fact that the ECM is sufficient to alter cell behavior, protein expression and drug 
response must be taken into account when designing and executing drug candidate 
validation studies and clinical trials. Currently, the vast majority of novel cancer 
therapeutics are screened for their efficacy against well-established cancer cell lines on 
high throughput, plate-based 2D systems104. This protocol completely ignores the native 
tumor mechano-environment as well as the effects of dimensionality and ligand binding 
which can also play a major role in drug efficacy. Our results also suggest that simply 
switching to 3D culture techniques is not enough to ensure a more robust and predictive 
model. Simply varying collagen concentration in our gels was sufficient to drastically 
alter cell behavior in one cell line, and this sensitivity to matrix properties must be 
considered when designing 3D culture systems. As we further our understanding of this 
relationship, it could be used to predict how tumors respond to different therapies. This 
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type of predictive knowledge is immensely valuable to clinicians, who could use it to 
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Figure 6-1: Simplified PI3K/AKT pathway map. In this study we examine the levels 
ofPI3K, mTOR and phosphorylated Protein S6 as indicators of cellular 
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Figure 6-2: U20S cell proliferation is unaffected by seeding density. U20S cells were 
seeded at various densities in 300/.1 L collagen gels. Cells were imaged 
immediately after seeding and 96 hours later. Data is presented as a ratio 
of the cell population after 96 hours to the cell population at initial 
seeding. 
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Figure 6-3: Proliferation ofU20S in 3D collagen gels with different concentration of 
live cell dye CMRA. Cells were grown in 3mg/ml collagen gels. Cells 
were counted immediately after seeding and 96h post-seeding. Data is 
presented as a ratio of 96h data to Oh data. No significant difference in cell 
proliferation was observed. 
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Figure 6-4: Proliferation of U20S on standard 2D tissue culture plastic compared to 
3D collagen gels. Cells were plated and immediately imaged. 96 hours 
later the cells were imaged again and the cell population was compared to 
the initial numbers. Cells in 3D show a dramatic reduction in proliferation, 
with approximately 1 cell division occurring over the 96h experiment. 
Cells in 2D showed much more aggressive growth, with cell doubling 
occurring every 24-30 hours. (p < .05 between 2D and 3D samples. 
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Figure 6-5: Proliferation ofMCF7 cells on standard 2D tissue culture plastic 
compared to 3D collagen gels. Cells were plated and immediately imaged. 
96 hours later the cells were imaged again and the cell population was 
compared to the initial numbers. Cells in 3D show a dramatic reduction in 
proliferation. Cells in 2D showed much more aggressive growth, with cell 
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Figure 6-6: Migration ofU20S cells on standard 2D tissue culture plastic compared to 
3D collagen gels. Cells were plated, and then immediately underwent 
timelapse imaging for 12 hours. Data here is the average speed of the cells 
over the course of the imaging sequence. Cell tracking was done using 
Imaris® software suite (Bitplane Inc., St. Paul, MN), with additional data 
processing done in MatLab®. Cells on tissue culture plastic moved 2.5 
times fasters than cells grown in 3D collagen gels (p < .01). 
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Figure 6-7: Protein expression blots from U20S cells grown on tissue culture plastic or 
in 3D collagen gels. Cells were plated, and then harvested 24 hours later. 
Celllysates were kept at -80°C if not immediately used. Cells in 3D had 
undetectable amount of pAkt, indicating a low level of overall pathway 
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* p < .05 with respect to data of asterisk color 
Figure 6-8: Ratio of U20S cell number in samples treated with Pil 03 to samples left 
untreated. Data here is presented as a ratio of cell count in drug treated 
sample to untreated controls. Cells in 4mg/ml collagen gels had a 90% cell 
survival rate after 8 days of drug treatment. Cells were more sensitive to 
the effects of the drug on 2D tissue culture plastic and in 3mg/ml gels. 
Interestingly, cells showed similar behavior in 3mg/ml and 4mg/ml gels 
when untreated, but had a markedly different response to PI103. All Day 8 
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Figure 6-9: Ratio of MCF7 cell number in samples treated with Pll 03 to samples left 
untreated. Data here is presented as a ratio of cell count in drug treated 
sample to untreated controls. As in figure 8, data is presented as a ratio of 
cell counts in the drug treated and untreated samples. Similar to U20S 
cells, MCF7 cell survived very well in 4mg/ml collagen gels when 
compared to cells in 2D. Unlike U20S cells, MCF7 cells in 3mg/ml 
collagen gels survived equally as well as cells in stiffer gels. Both ofthese 
conditions yielded cells with higher drug resistance than cells grown in 
monolayer. Although this behavior is not as complex as observed in U20S 
cells, it highlights the difference between 2D and 3D culture platforms. 
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Figure 6-10: Migration ofU20S cells over 6 hours in different culture conditions. Cells 
were stained with CMRA whole cell stain prior to being embedded in 
collagen. Cells were tracked by imaging the gels every 15 minutes for 6 
hours. Cell speed was calculated using a 3D displacement algorithm 























Figure 6-11: Western Blots for protein S6, PRAS, Akt and GAPDH in U20S cells on 
different substrates with and without drug treatment. Cells were plated, 
and then harvested 24 hours later. Celllysates were kept at -80°C if not 
immediately used. Drug treatment reduced levels of pS6 in all samples, 
consistent with the observed increase in cell doubling time. Paradoxically, 
this reduction was most pronounced in cells grown in 4mg/ml despite 
these cells showing the highest proliferative resistance to the effects of 
PI103. 
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Chapter 7: Development of the Embedded Spheroid Model 
7.1 Introduction 
Investigations of tumor behavior and preclinical drug assessments are 
increasingly employing 3D culture systems249 . This methodological shift is being 
informed by mounting evidence that these systems produce cellular behavior similar to 
what is seen in vivo, and that this difference is do more faithful microenvironment 
mimicry104'250 . This advantage has shown to produce more predictive results in 3D 
systems when compared to 2D. Most of the employed 3D systems come in one of two 
flavors: cell growth on non-adherent scaffold to induce cell-cell association or 
suspending single cells inside a porous natural or artificial scaffold to promote cell-matrix 
attachment251 '252. 
With regards to the latter technique, several polymer compositions including 
Matrigel™253'254, collagen175, chitosan255'256, silk203- 206, hyaluronic acid196 and synthetic 
polymers207- 212 are being used to create 3D scaffolds in an effort to recreate the native 
extracellular matrix (ECM)-like environments in vitro 257- 260. Although these systems 
represent an improvement over 2D by promoting normal cell behavior, they fail to 
recapitulate tumor macrostructure and hetereogeneitr50'261 . Most tumors present 
clinically as a cluster with a highly metabolically active surface, a quiescent sub-surface 
layer and an inner necrotic core of dead and dying cells. Cells embedded in 3D matrices 
are either totally isolated, or form small, numerous clusters. Solid tumors also possess 
mass transport limitations stemming from decreased surface area-to-volume ratios and 
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longer diffusion lengths, which are not present in single cells or small cell clusters261 ,262. 
Because of these characteristics of native tumors, promotion of normal cell 
macrostructure arid organization is crucial for promoting clinically relevant culture 
conditions for the study of cancer cell behavior and drug response. 
To address these challenges, methods of creating large cell clusters (>350 Jlm) are 
reported in the literature 263- 265 . These methods employ non-adherent surfaces to prevent 
cell-scaffold interactions, promoting the exclusive development of cell-cell contacts, and 
include spinning flasks, hanging drops, and agarose coated plates. The resulting spheroids 
are of a similar size to small tumors. Despite their size similarities, in vitro spheroids 
created in this way and in vivo tumors experience very different environmental cues, with 
the attachment-free scaffold providing none of the mechanical and biochemical signals 
found in clinical tumors266 . This is an important drawback to the use of the spheroid 
model, as cell-matrix attachments, ECM mechanics and soluble growth factor signaling 
can drastically affect cell differentiation and survival267 . The interplay between the ECM 




. Therefore, there is a need for additional methods to prepare stable and 
reproducible models which mimic the native tumor environment while being large 
enough to merit comparison with clinically relevant native tumors. 
To overcome the deficiencies of standard 3D models and recapitulate normal cell 
adhesion, cell-ECM interaction, biochemical state, mechanical properties, and tumor 
macrostructure, we present a scalable and reproducible method for embedding and 
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manipulating cancer cell spheroids inside a 3D collagen gel. This spheroid-based model 
is easy to produce, cost-effective, quantitative, and high throughput with low setup time 
while providing opportunities to study proliferation, invasion, enzymatic activity, and 
antitumor agent activity for clinically relevant data acquisition. It builds upon the 
previous spheroid and spheroid-collagen models,268- 273 and enables individual spheroid 
manipulation along with whole spheroid and single cell analyses. 
Specifically, this model consists of a tumor cell spheroid grown on agarose-coated 
wells that is transferred into type one collagen gels (Figure 7-1). The previously 
demonstrated ability to freely manipulate the properties ofthe collagen gels allow us to 
investigate the effects of ECM mechanics ligand density on spheroids behavior. We 
demonstrated the applicability of this system to multiple cancer types, including both 
human osteosarcoma and adenocarcinoma cell lines. The system is sensitive to cell 
seeding number and collagen mechanical properties, and allows documentation of 
metabolic activity over time. Finally, we highlight the potential of this spheroid model for 
quantitative evaluation of paclitaxel, a clinically used first line anti-cancer drug, activity 
via two different drug delivery routes. 
7.2 Methods 
7.2.1 Cell Culture 
Experiments were performed on the pediatric osteosarcoma cell line U20S and/or breast 
adenocarcinoma cell line MDA-MB-231 (ATCC, Manassas, VA). Both cell lines are 
well established and have been extensively studied in cancer research applications, and 
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much is known about their protein expression and secretion profiles. Both cell lines 
express high levels of E-Cadherin and readily form spheroids 274•275 . Cells were cultured 
in complete RPMI (U20S) or DMEM (MDA-MB-231) media supplemented with 10% 
fetal calf serum and 1% penicillin-streptomycin solution (1 0,000 IU/mL penicillin; 
10,000 flg/mL streptomycin). Cell cultures were maintained in 2D mono layers in a 
humidified incubator at 3 7°C, 5% C02. 
7.2.2 Spheroid Formation 
Cell aggregation was induced by growing cell suspensions in agarose-coated 96 well 
plates. Briefly, 1.5% (wt/vol) agarose solution was made by combining 0.15 g agarose 
(Sigma-Aldrich, St. Louis, MO) with 10 mL PBS. This solution was microwaved until 
agarose dissolution(~ 30s). The solution was kept on a hot plate during the well coating 
process, to prevent premature gelation. To prepare the 96-well plate, 70 uL ofthe hot 
agarose solution was pipetted into each well and allowed to cool for 20 minutes. 
Separately, cell monolayers were detached from their culture flask via a standard 
typsinization protocol. Cells were counted and re-suspended in media to the desired 
concentration. Next, 100 uL ofthe cell suspension was added to each agarose-coated 
well. After 72 hours, the resulting cell aggregates were lifted via gentle pipetting and 
were immediately seeded into collagen gels as described below. 
7. 2. 3 Collagen Embedding 
Spheroids were transferred into an un-polymerized collagen gel following a published 
procedure 175• High Density Rat Tail Type I collagen (BD Biosciences) was diluted to 10 
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mg/mL in 0.02 N acetic acid. The resulting solution was combined 1:1 with a buffer 
solution (100 mM HEPES in 2x PBS, pH 7.3). This mixture was then further diluted with 
PBS to the experimental collagen concentration (2-5 mg/mL). This solution self-
polymerizes into a gel after 1 hour at 37 °C. Tumor cell spheroids were added to 100uL 
of unpolymerized collagen solution in each well of a 96 well plate. After 1 hour, 100 uL 
of media or media with drug was added on top of the gel. This media was removed and 
replaced every 24 hours. 
7. 2. 4 Tracking Spheroid Growth 
After collagen embedding, spheroids were imaged every 24 hours for the duration of the 
experiment. Images were acquired on a DMI600B microscope (Leica, Solms, Germany) 
with an ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) in a 
spinning disc confocal setup (Yokogawa, Tokyo, Japan). Imaging was done using Micro-
Manager 1.4 Software (http://www.micro-manager.org). Resulting images were analyzed 
with ImageJ software to measure spheroid diameter. 
7. 2. 5 Live/Dead Staining 
MDA-MB-231 spheroids were stained with Calcein AM and Eithidium homodinier-1, for 
live and dead cells, respectively 72 hours after transferring to collagen (4 mg/mL) 
(Molecular Probes, Eugene, OR). Images were acquired as previously described with the 
addition oflaser excitation of the sample at 488 and 561 nm. 
7. 2. 6 Disaggregation of Spheroid for Metabolic Activity Assessment 
MDA-MB-231 spheroids were transferred into collagen (4 mg/mL) for 24 hours prior to 
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disaggregation by collagenase I treatment (2.38 mg/mL) (Life Technologies, Carlsbad, 
CA) in Hank's Buffered Salt Solution at 37°C for one hour. Next, cells from both 
spheroids and monolayer culture were seeded for 12 hours. Cell viability was then 
assessed via exposure to the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2- ( 4-sulfophenyl)-2H-tetrazolium) cell proliferation assay 
(Sigma, St. Louis, MO). Metabolic activity was calculated as the percentage of the 
positive control absorbance at 490 nm. 
7. 2. 7 Nucleic Acid Extraction 
Nucleic acid was extracted from fully embedded spheroid samples using the Trizol 
Reagent without additional purification or disaggregation steps(Life Technologies, 
Carlsbad, CA). Subsequent RNA concentration was then measured with a NanoDrop Lite 
(Thermo Scientific, Wilmington, DE). Ten 20,000 cell MDA-MB 231 spheroids yielded 
4.735 1-lg RNA. 
7.2.8 Nanoparticle Preparation 
Paclitaxel-loaded expansile nanoparticles (Pax-eNP) were prepared as previously 
described 276 . Briefly an oil-in-water mini-emulsion technique was used to polymerize 
monomer ( 5-methyl-2-(2,4,6-trimethoxyphenyl)-1 ,3-dioxan-5-yl)methyl methacrylate 
with crosslinker, 1,4-phenylene bis(2-methylacrylate) and the addition of(5% wt/wt) 
paclitaxel (MP Biomedicals, Solon OH). A non-loaded fluorescently labeled eNP was 
made in a similar manner using a covalently incorporated rhodamine co-monomer. 
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Paclitaxel was selected because of its clinical use in the treatment of metastatic 
breast cancer. Paclitaxel was discovered in the 1960s by a National Cancer Institute-
sponsored study where extracts from the Taxus brevigolia tree displayed anti-neoplastic 
activity against several tumors 277 . The mechanism of action is through binding and 
subsequent stabilization of microtubules which prevents dynamic reorganization278 . Due 
to insolubility the compound is dissolved in Cremophor El (1: 1 solution of ethanol and 
polyoxyethylated castor oil) for in vivo administration279 . 
7. 2. 9 Spheroid Treatment with Different Drug Delivery Methods 
MDA-MB-231 spheroids were made with 20,000 cells and subsequently embedded in 
collagen gels ( 4 mg/mL) for 24 hours. Spheroids were exposed to either 100 ng/mL or 
1000 ng/mL paclitaxel delivered via bolus dose (paclitaxel cremophor/ethanol) in the 
media or via Pax-eNP. In both cases, cells were incubated with the drug treatment for 24 
hours and then spheroid size was monitored over one week. Analogous treatment was 
performed with fluorescently labeled eNPs, and imaged after treatment for 24 hours upon 
excitation of 561 nm. 
7.3 Results 
7. 3.1 Spheroid Size is Linearly Dependent on Cell Seeding Number 
To demonstrate the scalability and reproducibility of spheroid formation, we compared 
cell seeding number to resulting spheroid size. Figure 7-2 and Figure 7-3 show the 
resulting trend-line for U20S and MDA-MB-231 cell lines respectively. In both cases, 
the data was fit to the expected power-law curve (R2 >0.98) with very small sample to 
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sample error (<3% in U20S cells and <5% in MDA-MB-231 cells). The horizontal error 
bars represent the cell counting errors arising from using a standard hemocytometer, 
which is estimated at less than 10%. The results indicate that homogenous samples are 
reproducibly prepared and that spheroid size can be precisely controlled. 
7. 3. 2 Collagen Gel Properties Affect Spheroid Growth 
By embedding spheroids inside a natural matrix, we hoped to induce biological relevant 
cell-ECM interactions. We also strove to investigate how changing the nature of the 
scaffold, to model the highly variable nature of the in vivo ECM, affects cell behavior. 
Our chosen scaffold, type 1 collagen gels, can be prepared with different collagen content 
to directly control the pore size, attachment ligand density, and mechanical properties of 
the gels121• We therefore investigated the effect of changing the collagen gel content 
surrounding the embedded spheroids. We seeded spheroids in collagen gels with different 
collagen content, ranging from 2-5 mg/mL. These gels possess linear elastic moduli that 
vary over an order of magnitude, ( ~ 10-200 kPa) enabling us to expose the spheroids to a 
wide range of mechanical environments 280•281 • Figure 7-4 and Figure 7-5 show the line 
and contour plot of both MDA-MB-231 and U20S spheroid growth, respectively, over 
72 hours in different collagen gels. In Figure 4a, the X-axis represents time and the 
legend entries represent different gel collagen densities. In figure 4b, the colored XY-
plane represents the spheroid size under those conditions. The spectrum, from red to 
purple indicates increasing spheroid diameter. We note that in general, U20S spheroids 
showed a standard deviation in diameter of 3-5% while the MDA-MB-231 spheroids 
showed slightly higher error of approximately 6-8%. There is a significant difference in 
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the size of spheroids in different collagen gels after 3 days. In U20S cells, spheroids 
grow the largest in 4 mg/mL collagen gels while MDA-MB-231 cells exhibit optimal 
growth in 2mg/mL gels. 
7. 3. 3 Tumor Like Characteristics 
After 72 hours of growth within collagen, live/dead staining revealed a pattern of 
metabolic activity and apoptosis. The ethidium homodimer-1 fluorescence indicates 
compromised membrane and subsequent binding to nucleic acids. Calcein AM staining 
shows metabolically active cells. Figure 7-6 demonstrates a spheroid with a 
metabolically active ring of cells on the periphery combined with necrosis or apoptosis 
within the core. 
Next, the spheroids embedded within collagen for 24 hours, were disaggregated, 
and seeded in a monolayer. To account for cell growth during spheroid formation, 
spheroids on agarose were counted after disaggregation. After 96 hours, spheroids seeded 
with 20,000 cells had 60,125±8,819 cells (n=4). Figure 7-7 shows a comparison ofthe 
cells grown in a spheroid compared to cells grown solely in a monolayer. The cells from 
the spheroid exhibit a lower MTS activity value and comparable to 30,000 cells grown in 
a monolayer, and significantly different then the corresponding 60,000 cells grown in 2D, 
indicating that the overall metabolic rate is lower (p<<0.05). 
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7.3.4 Spheroid Response to Different Drug Delivery Methods 
We treated MDA-MB-231 spheroids with paxclitaxel in either bolus or 
expansilenanoparticle delivery (eNP) formats276•282 . Expansile nanoparticles are designed 
to more efficiently transport the loaded drug into the cell, where pH-mediated drug 
release occurs in the endosome. Figure 7-8 demonstrates that eNPs have fully penetrated 
the spheroid after 24 hours. The spheroid response to paclitaxel is similar for both the low 
and high dose (lOOng/mL versus lOOOng/mL). There is, however, a significant difference 
in spheroid response to the two delivery methods, with Pax-eNP delivery resulting in 
greater size reduction to spheroid diameter. As shown in Figure 7-9, both treatments 
showed a statistically significant (p < 0.05) spheroid size reduction when compared to 
control samples. 
7.4 Discussion 
Identification and validation of novel therapeutics for cancer treatment has relied 
on expensive or irrelevant models of cancer biology for the last two decades. The models, 
including in vitro cell toxicity assays, tumor bearing small animal models, and large 
animal biodistribution/toxicity studies, do not provide an appropriate platform for 
promoting in vivo cell behavior, resulting in non-predictive results. While animals do 
provide a physiological model for evaluation of drug efficacy and toxicity, they are 
expensive, labor intensive, and low throughput. In contrast, 2D momlayer based cell 
culture methods are rapid and high throughput, but possess serious limitations including 
lack of ECM, artificial and unrealistic mechanical environments, tumor macrostructure, 
and diffusion gradients 26 1. The results obtained with these 2D monolayer models, as 
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such, do not always reflect or predict the in vivo performance. The use of cancer 
spheroids embedded in ECM-like scaffolds has the potential to overcome the 
shortcoming of both of these methodologies, allowing for accurate assessment of drug 
candidates in a cheap, rapid protocol. Building on the successes of previous 3D 
spheroids,268- 273 we extend this methodology and report a scalable method for preparation 
of single spheroids of controllable size incorporated into collagen gels as a tumor model. 
Using cell lines derived from two different carcinomas (human osteosarcoma, 
U20S, and adenocarcinoma, MDA-MB-231, cell lines), we demonstrate the ability to 
reproducibly create spheroids of varying size, as dependent on seeding number. 
Osteosarcoma and adenocarcinoma spheroids are prepared ranging from;:::; 115 to 395 and 
200 to 875 11m in diameter, respectively, with the larger spheroids being attractive models 
of cancer development, progression and drug response (Figure 2). Because the spheroid is 
embedded in collagen, biologically relevant attachment sites and degradation properties 
allow for cell ingrowth and interaction with other cells, as observed in vivo. Tunable 
mechanical and biochemical properties allow for more biomimetic tumor-matrix 
interactions. 
The two cell lines, osteosarcoma and adenocarcinoma, show very different 
spheroid behavior in different in collagen gels varying in modulus from ~ 1 0 to 200 kPa. 
As shown in Figures 3 and 4, U20S and MDA-MB-231 spheroids ranging from ;:::; 335 to 
395 and 550 to 800 11m in diameter, respectively, are observed based on the mechanical 
properties of the collagen gels. The largest osteosarcoma spheroids are present in the 
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stiffest gel while the largest adenocarcinoma spheroids are found in the softer gel. The 
preference of bone and breast cancer cells for stiffer and softer gels, respectively, 
indicates an optimal mechanical environment for these cells, and is consistent with other 
reports 283-285. 
Since collagen gels provide suitable optical properties for light-based imaging, 
this model allows for direct evaluation of spheroid shape, morphology, and surface 
characteristics as well as analysis after histological or classical optical live/dead stains. 
Figure 5 shows an optical image of a MDA-MB-231 spheroid after Calcein AM/ 
ethidium homodimer-1 staining. The green, metabolically active ring of cells on the 
periphery, surround the red cells indicative of rampant necrosis or apoptosis at the core. 
The presence of these tumor hallmarks indicate that the biological causes of tumor 
heterogeneity, 02/nutrient gradients and improper waste removal, are present in this 
model 250,253 . The observed reduction in growth in single cell grown in 3D, as well as the 
restrictions placed on cell metabolic activity by unavailability of key nutrients lead to the 
reduction in growth rates between the spheroid and its monolayer counterpart 250,253 . To 
further assess cell growth and viability in our model, collagen embedded MDA-MB-231 
spheroids were disaggregated, seeded in a monolayer, and analyzed for metabolic 
activity. As shown in Figure 6, cells from the spheroid display a relatively lower MTS 
activity value compared to those grown in 2D. In fact, 60,000 spheroid-grown cells 
exhibit the activity of approximately 30,000 cells grown in a monolayer. This latter result 
documents that our spheroid model is amenable to single cell analyses (e.g., cell uptake, 
metabolic activity, DNA studies), in addition to whole spheroid experiments. 
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Furthermore nucleic acid extraction will allow insights into global changes in genetic 
expressiOn. 
This system provides a platform for studying biologically relevant behaviors of 
cancer cells in an in vitro setting, and this feature makes the model amenable to a number 
of future investigations. One potential application of this model is as a tool for evaluating 
drug delivery devices and quantifying their impact on tumor size. Diffusion through the 
collagen ECM and spheroid body, cellular uptake and chemical modification are all 
barriers to drug efficacy, and must be considered during the development cycle. These 
delivery challenges do not arise in monolayer cell cultures, but are present in our 
spheroid model. For these reasons we expect cell spheroids to exhibit differential drug 
response to monolayer cells, and that their behavior will be sensitive to drug delivery 
methodology. This sensitivity has been observed in clinical tumors, where 
pharmacological kinetics play an important role in drug efficacy 286 . For these studies, we 
chose a bolus dose ofpaclitaxel, as is practiced in the clinic287, and a paclitaxelloaded 
expansile nanoparticle 276. The expansile nanoparticle is designed to localize to the tumor 
and once inside the tumor ECM or tumor cell where the pH is mildly acidic (pH= 6.0 
and 5.5-6.5 for the tumor ECM and endosome, respectively), the particle will expand or 
swell to release the paclitaxel to afford focused localized tumor delivery. 
Paclitaxel delivered via expansile nanoparticle showed strikingly different 
efficacy than bolus delivery (Figure 8). Although somewhat effective at slowing cell 
growth, bolus delivery drug effect was significantly less than that of the expansile 
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nanoparticle treatment. Cells were dosed with rhodamine labeled eNPs to verify that 
eNPs were taken up by the cells, even through the diffusive barrier of the spheroid body. 
Confocal microscopy confirmed that the eNP dispersed throughout the spheroid after 
diffusing through the collagen (Figure 7). The eNPs are designed to penetrate the 
spheroid, invade cells and then release the loaded drug, as compared to bolus delivery of 
Pax, where the tumor is transiently exposed to the drug. Previous studies in 2D have 
shown that bolus delivery and eNP treatment with loaded paclitaxel has no difference in 
efficacy, suggesting that this difference is specific to 3D conditions282 . In a different 
study using an in vivo mode, eNP delivery of paclitaxel was compared to bolus IV 
delivery. A bolus doses ofpaclitaxel results in a small reduction in tumor size, while the 
Pax-eNP treatment significantly reduces tumor growth after 6 weeks (p<0.05i82 . The 
spheroid model better replicates the observed invivo response of the two different 
paclitaxel delivery methods. 
Several studies report that cells grown in monolayer are more sensitive to radiation 
exposure when compared to in vivo tumors288- 290 . Equal doses of radiation to a malignant 
cell line in either a monolayer or a murine tumor had a greater effect on cell survival on 
the monolayer288 . This discrepancy is attributed to increased cellular robustness due to 
cell-cell proximity, paracrine signaling, and hypoxic core 291 ,292 . Spheroids with 3-D cell 
contacts and hypoxic regions, which reduce the presence of reactive oxygen species, are 
more predictive than cell monolayer models of in vivo radiation response291 - 294 . When a 
human xenograft melanoma line was treated with radiation both as in vitro spheroids and 
in vivo murine tumors cell growth delay in spheroids correlated with survival in in vivo 
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tumors 293 . In addition to radiation, spheroids are being used as a testing model for 
multiple experimental treatments such as photodynamic therap/95 , gene therapy296, and 
radioimmunotherap/97• These examples highlight the need for and relevance of using 3D 
spheroids for assessing existing treatment methods and exploring novels treatments. 
Although a step forward, these spheroid-based experiments disregard contributions from 
the extracellular matrix. The collagen embedded spheroid model would further increase 
the relevance of the spheroid system, as a tool for therapy assessment and discovery. 
While no in vitro tumor model can fully recreate the in vivo environment encountered by 
cancer cells, our model moves the field forward due to its numerous advantageous 
qualities stemming from the marriage of spheroids and native ECM scaffold. Previous 3D 
models have shown differential cell behavior when compared to 2D systems, but our 
model extends these advantages to include the study of single cell masses of controllable 
size incorporated into a collagen gel. This model was sensitive enough to detect 
differences in paclitaxel efficacy based solely on delivery methods; results which 
mirrored those of previous in vivo but were now shown in 2D systems. This result 
highlights the importance of testing drug delivery methods in tandem with drug 
development, as the two have synergistic effects on observed efficacy. 
The key features of this tumor model are: 1) a multicellular spheroid of controllable size; 
2) a collagen based ECM structure surrounding the spheroid; and 3) a spheroid with a 
metabolically active outer layer and necrotic core. These features allow faithful recreation 
of in vivo conditions while remaining high throughput, scalable and quantitative, all 
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features that are required for large scale drug development efforts263- 265 . Our spheroids 
can also be studied using classical clinical techniques, including sectioning, cell or 
protein staining, time-lapse microscopy and DNA/RNA/protein isolation. Deeper studies 
can take advantage of the ability to remove the spheroids from the collagen gel for single 
cell investigations including F ACs, live/dead and metabolic activity assays. 
The combination of whole spheroid techniques with single cell analysis allows for in-
depth investigations into basic cancer cell behavior from the tissue to single molecule 
scales. In summary, the 3D biomimetic culture platform described here facilitates the 
study ofbasic cancer cell behavior, the evaluation of new anticancer agents, the role of 
drug delivery devices in optimizing the tumoral response, and the development of 
simulation software for data modeling and predictions. All of these quantitative and semi-













3. Nucleic acid extraction 
Single Cell Analysis 
1 . Flow cytometry 
2. Metabolic activity 
Media 
Figure 7-1: Embedded Spheroids Procedure: Spheroid formation is encouraged by 
placing a suspension of cells (red) in media (pink) on agarose (yellow) 
coated wells. After 72 hours, a spheroid is formed, and then transferred 
























MDA MB231 Tumoroid Size vs 
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Equation y lZ a+ b*x 
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Residual Sum 98.13682 
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Figure 7-2: Ratio of embedded MDA-MB-23 1 cells to resulting spheroid volume. The 
linear trend indicates that there is not an appreciable accumulation of cells 
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U20S Tumoroid Size vs 
# of Seeded Cells 
y = a+ b'x 
Instrumental 
Residual Sum 42 .23069 
of Squares 
Pearson's r 0.99773 
Adj. R-Square 0.99433 
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Figure 7-3: Ratio of embedded U20 S cells to resulting spheroid volume. The linear 
trend indicates that there is not an appreciable accumulation of cells over 
the 72h formation period. 
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Figure 7-4: MDA-MB 231 Spheroid Growth in Collagen: Metastatic breast cancer 
spheroids grown in collagen gels with varying mechanical properties 
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Figure 7-5: U20S Spheroid Growth in Collagen: Bone cancer spheroids grown in 
collagen gels with varying mechanical properties demonstrated the most 
growth in 4-5 mg/mL, growing less in softer gels. 
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Figure 7-6: Pattern of Metabolic Activity: A spheroid in collagen was stained with a 
calcein based stain (green) to show metabolically active cells and an 
ethidium based stain (red) to demonstrate cells with a compromised 
membrane. The red staining on the interior indicates a mostly dead core, 
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Figure 7-7: Metabolic Activity of Spheroids. Disaggregated spheroids were plated in a 
monolayer and the metabolic activity was compared to cells grown only in 
a monolayer. Although there were approximately 60,000 cells, the overall 
metabolic level is comparable to 15,000 cells. 
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Figure 7-8: Nanoparticle Penetration: Within 24 hours fluorescently labeled 
nanoparticles were able to fully penetrate a 20,000 cell MDA-MB 231 
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Figure 7-9: Spheroid Treatment with Nanoparticles: Paclitaxel, a chemotherapeutic 
drug was delivered via bolus dose or nanoparticles for 24 hours before the 
treatment was removed. The nanoparticle delivery method was the most 
effective at reducing spheroid size. 
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Chapter 8: Embedded spheroid model as a tissue specific analog 
8.1 Introduction 
The ability to create biomimetic 3D environments in vitro has been a critical 
development in cancer research 168 . It is now well established that the specific properties 
of the culture system used affect cell behavior, including mechanical properties, 
component proteins, integrins-binding ligand density, pore size and growth factor 
content112. Despite our deepening understanding of how these factors contribute to cell 
behavior, relatively little work has been done on calibrating these properties to a specific 
in vivo condition. It is one thing to design a scaffold with tunable properties, it is quite 
another to set those properties to match a target tissue or disease state. The wealth of 
reports on how tissue architecture and microenvironment properties affect cell behavior 
and disease state suggest that such a targeted approach is critical to begin harvesting 
clinically relevant data from these systems36,25 1 ,253 . 
In most models of disease state, the target disease arises in a specific tissue or cell 
type, making the choice of matrix properties relatively simple. For cancer, no such 
broadly applicable properties exist, as tumors dynamically remodel their 
microenvironment, meaning that the ECM properties change with time. Additionally, the 
ability of tumors to metastasize into distant tissue with distinct, and often drastically 
different properties means that in vitro models need to recapitulate multiple 
microenvironments36'69 . Creating a 3D scaffold to mimic breast tissue and using it to 
study late stage tumor behavior or metastasis forming potential of breast cancer cells does 
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not recapitulate in vivo conditions, and can lead to misleading results. 
This type of shortfall is not only found in vitro, but in xenograft models as well. 
Cancer cells of many different types of tumors are regularly grown in subcutaneous 
murine models, despite the fact that these cells are never found in this environment 
clinicallr98 . Bone cancer cells experience a very different microenvironment then what 
they are exposed to subcutaneously. Indeed, these types of xenograft models often give 
drastically different results than orthotopic models with the same cellline299- 301 . Despite 
this evidence, preclinical drug evaluation is often done without these considerations in 
mind. This wastes time and money that could be used on potentially life-saving 
treatments. 
These types of design constraints are well known to tissue engineers, who go to 
great lengths to insure in vivo-like properties in their scaffolds112. This focus is most 
commonly seen in bone regeneration studies302, mostly because bone tissue is orders of 
magnitude less compliant than other soft tissues. Extensive computational methods are 
used to ensure optimal approximation of tissue properties, including density, compliance, 
and pore size303 . Without these considerations, bone replacement scaffolds are ineffective 
at promoting wound healing. Similarly, engineering of replacement heart valves and 
myocardial implants require specific properties and robustness due to their experience of 
a constant load in vivo304 . 
To address these shortcomings in common 3D models of cell culture, we have 
used our previously reported embedded spheroid model inside Type 1 collagen gels with 
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varying collagen content. Breast tumors become stiffer and increase local collagen 
content over time295 , so increasing collagen content in our gels simulates early-, mid- and 
late-stage tumors. Bone tumors begin in a rigid environment, and are approximated by 
the gels with the highest collagen content305 . These gels have been used previously, with 
cells demonstrating differential behavior based solely on changing collagen content. 
Here, we evaluate the effects of receptor tyrosine kinase (R TK) agonism and inhibition 
on breast and bone cancer cells in the collagen gels. 
RTK inhibition has been extensively studied as a potential treatment for 
osteosarcoma19 and breast cancer306. Despite promising pre-clinical results in 
osteosarcoma, RTK inhibition is not used on osteosarcoma patients due to poor clinical 
results. The pre-clinical results that suggested possible efficacy were carried out in 
2D307•308, soft 3D gels309 or subcutaneously in murine xenograft models309. Here, we 
attempt to recapitulate the efficacy ofRTK inhibitors on U20S cells in soft collagen gels, 
while also demonstrating U20S resistance to these treatments in stiffer, more bone-like 
gels. Similar trends have been observed in breast cancer. Preclinical data carried out in 
2D310 or in a mouse xenograft model showed311 promise, but subsequent clinical trials 
failed to reproduce the pre-clinical efficacy312'313 . Currently, only the Her2 receptor, a 
receptor related to epidermal growth factor receptor, is utilized as a molecular target for 
breast cancer treatment, and only when tumors are shown to overexpress the receptor314. 
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8.2 Methods 
8. 2.1 Cell Culture 
Experiments were performed on the pediatric osteosarcoma cell line U20S and/or breast 
adenocarcinoma cell lines MDA-MB-231 and BT -20 (ATCC, Manassas, VA). BT -20 
cells are pre-metastatic and harvested from the primary tumor in breast. Conversely, 
MDA-MB-231 were derived from a pleural effusion; they show preferential metastasis to 
bone and are one of the most commonly used breast cancer cell lines. All 3 cell lines are 
well established, have been extensively studied in cancer research applications, have well 
characterized protein expression and secretion profiles and readily form spheroids 274,275 . 
Cells were cultured in complete RPMI (U20S, BT -20) or DMEM (MDA-MB-231) 
media supplemented with 10% fetal calf serum and 1% penicillin-streptomycin solution 
(10,000 IU/mL penicillin; 10,000 Jlg/mL streptomycin). Cell cultures were maintained in 
2D mono layers in a humidified incubator at 3 7°C, 5% C02• 
8.2.2 Jkfaterials 
PDGF-BB was purchased from R&D Systems and used at an experimental concentration 
of 5ng/ml. PDGFR and TGFBR inhibitors were purchased from CalBiochem and used at 
an experimental concentration of 0.5uM and 1 uM respectively. PtHRP ELISA kits were 
purchased from Biotang Inc. (Waltham, MA) and carried out according to the 
manufacturers instructions. PtHRP is a powerful activator of osteoclast activity, and is 
often expressed by cancer cells invading bone tissue. VEGF ELISA kit was purchased 
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from Fisher Scientific (Hampton, NH) and carried our according to the manufacturer's 
instructions. 
8.2.3 Spheroid Formation 
Cell aggregation was induced by growing cell suspensions in agarose-coated 96 well 
plates. Briefly, 1.5% (wt/vol) agarose solution was made by combining 0.15 g agarose 
(Sigma-Aldrich, St. Louis, MO) with 10 mL PBS. This solution was microwaved until 
agarose dissolution(~ 30s). The solution was kept on a hot plate during the well coating 
process, to prevent premature gelation. To prepare the 96-well plate, 70 uL of the hot 
agarose solution was pipetted into each well and allowed to cool for 20 minutes. 
Separately, cell mono layers were detached from their culture flask via a standard 
typsinization protocol. Cells were counted and re-suspended in media to the desired 
concentration. Next, 100 uL ofthe cell suspension was added to each agarose-coated 
well. After 72 hours, the resulting cell aggregates were lifted via gentle pipetting and 
were immediately seeded into collagen gels as described below. 
8. 2. 4 Collagen Embedding 
Spheroids were transferred into an un-polymerized collagen gel following a published 
procedure 175 • High Density Rat Tail Type I collagen (BD Biosciences) was diluted to 10 
mg/mL in 0.02 N acetic acid. The resulting solution was combined 1:1 with a buffer 
solution (100 mM HEPES in 2x PBS, pH 7.3). This mixture was then further diluted with 
PBS to the experimental collagen concentration (2-5 mg/mL). This solution self-
polymerizes into a gel after 1 hour at 3 7 °C. Tumor cell spheroids were added to 1 OOuL 
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of unpolymerized collagen solution in each well of a 96 well plate. After 1 hour, 100 uL 
of media or media with drug was added on top of the gel. This media was removed and 
replaced every 24 hours. 
8. 2. 5 Tracking Spheroid Growth 
After collagen embedding, spheroids were treated with exogenous PDGF, PDGFR 
inhibitor or dual PDGFR and TGFBR inhibitors. Media was replaced with fresh media 
containing additional drug treatment every 24 hours. Spheroids were then imaged every 
24 hours for the duration of the experiment. Images were acquired on a DMI600B 
microscope (Leica, Solms, Germany) with an ImagEM EM-CCD Camera (Hamamatsu 
Photonics, Hamamatsu, Japan) in a spinning disc confocal setup (Yokogawa, Tokyo, 
Japan). Imaging was done using Micro-Manager 1.4 Software (http://www.micro-
manager.org). Resulting images were analyzed with ImageJ software to measure spheroid 
diameter. 
8. 2. 6 Tracking Cell Migration and Extravasation 
Prior to spheroid seeding, cells were incubated with 5~-tM CMRA (Molecular Probes) in 
serum free media for 45 minutes. After staining, 30,000 cells were added to each well of 
an agarose-coated 96-well plate. 72h later, spheroids were transferred to collagen gels as 
described above. To compare the effects of tumor macrostructure on cell migration, 
diffusely embedded cell samples were also created. These cells were stained with CMRA 
as above, and seeded directly into collagen gels at a density of 30,000 cells per well. 
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Spheroids and sparsely embedded cells were treated either with PDGF, PDGFR inhibitor 
or both PDGFR and TGFBR inhibitors. 
Images were acquired over 24 hours using a DMI600B microscope (Leica, Solms, 
Germany) and ImagEM EM-CCD Camera (Hamamatsu Photonics, Hamamatsu, Japan) 
using a spinning disc confocal setup (Yokogawa, Tokyo, Japan). Imaging was done using 
Micro-Manager 1.4 Software (http://www.micro-manager.org). Confocal images were 
analyzed using !MARIS 7.3.2 (Bitplane Inc., St. Paul, MN). Cells were analyzed using 
the spot tracking and surface detection routines. Spot tracking gives the centroid position 
of each cell at each time point and was used to track cell number and cell movement over 
time. Surface detection outlined the 3D surface of each cell, and was used for cell size 
and shape measurements. Cell size and track duration were used as excluding 
measurements to reject overly small cells or cells that were not tracked for longer than 8 
hours. For quantification of extravasation from spheroids, an additional filter was used to 
rejected cells moving within the spheroid body. 
8. 2. 7 Analysis of Cell Secretions via ELISA 
To assess the secretion profile ofthe cells, analysis of the supernatant was carried out via 
ELISA. Spheroids or sparsely embedded cell samples were created as described above 
and treated with vehicle or PDGF. 120h later, supernatant media was harvested and 
analyzed according to the manufacturer's instructions. 
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8.3 Results 
8.3.1 U20S Proliferation, Migration, Protein Secretion and Drug Response 
U20S spheroid growth was quantified in collagen gels with collagen content of2, 3, 4 
and 5mg/ml in response to PDGFR inhibition or both PDGFR and TGF~R inhibition. 
Results are shown in Figure 8-1. Control spheroids showed the highest growth in the 
stiffest collagen gels (4 and 5mg/mL), indicating a preferred mechanical environment for 
proliferation. Interestingly, drug response was also differentially modulated in different 
collagen gels, with RTK inhibition showing significant efficacy in reducing spheroid 
growth in 2, 3 and 4mg/mL collagen gels. Conversely, the inhibitors had a minimal effect 
on U20S spheroid in 5mg/mL gels. This result is consistent with the observation that 
RTK inhibition is ineffective against bone cancer cells orthotopically, but effective when 
evaluated at other tissue sites. 
U20S migration as single cells or away from spheroid masses was also assessed. 
Results are shown in Figure 8-2 (single cell) and Figure 8-3 (Spheroid Extravasation). 
The calculated migration speed is very low ( <8umlhr) for single cell samples, and is 
probably mostly attributed to noise in the calculation of cell centroid. For extravasation 
samples, speeds were higher, but error bars were large as a result of only a few cells 
leaving the spheroid body. These observations indicate that migration measurements in 
this cell line are untrustworthy and inconsequential. 
Finally, U20S secretion of both VEGF and PtHRP was assessed. Results are 
shown in Figure 8-4 (VEGF) and Figure 8-5 (PtHRP). PtHRP expression was relatively 
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unchanged in different collagen gels, indicating that its expression is not regulated by 
microenvironment in this cell line. VEGF expression was similar in 2, 3 and 4mg/ml gels, 
but was drastically reduced in the stiffest collagen gels. This result is consistent with 
U20S cells being non-angiogenic in vivo, but showing angiogenic potential in a 
chorioallantoic membrane assay (CAM) carried out in the very soft environment of a 
chick embryo309. 
8.3.2 MDA-MB-231 and BT-20 Spheroid Growth 
To assess the growth potential of pre- and post-metastatic breast cancer cell lines in 
collagen gels mimicking different tumors, spheroid diameter was tracked. Results are 
shown in Figure 8-6 and Figure 8-7. In MBA-MD-231 cells, control groups showed 
similar growth across all collagen gels, consistent with the observation that MDA-MB-
231 can colonize many different tissue types. The collagen gels did promote different 
drug response however, with stiffer gels reducing the efficacy ofRTK inhibitors. This 
effect was not significantly different when comparing the two inhibitors alone or in 
tandem. When MDA-MB-231 spheroids were treated with PDGF, they showed 
drastically increased growth, but only in softer gels. As with the inhibitors, the cells were 
insensitive to the treatment in 5mg/ml gels. 
BT -20 spheroids showed a similar trend, with spheroids in stiffer gels being 
relatively insensitive to the anti-proliferative effects ofPDGFR and TGFBR inhibition. 
Even in the softest gels, the effect ofRTK inhibition was minimal in BT-20 spheroids, 
consistent with these drugs failing pre-clinical and clinical evaluations as treatments for 
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breast cancer. Spheroids spiked with PDGF showed very little difference in growth, with 
the exception being a modest increase in late time point spheroid growth in 2mg/mL 
collagen gels. 
8.3.3 MDA-MB-231 and BT-20 Migration and Extravasation 
Unlike U20S cells, MDA-MB-231 are highly motile in 3D environments. To 
quantitatively assess the role of collagen content, RTK inhibition and exogenous growth 
factor delivery on cell migration, MDA-MB-231 cell speeds were analyzed both in 
diffuse cell suspensions and away from spheroid bodies. Results are shown in Figure 8-8 
(Single Cell) and Figure 8-9 (Spheroid Extravasation). Single cell migration showed the 
expected decrease with increasing collagen content, consistent with the steric hindrance 
associated with increased collagen fibril density and decreased pore size. Interestingly, 
when examining cells extravasating from spheroids, this trend was not observed in cells 
treated with PDGF. Instead, cell speed dramatically increased in higher density gels. This 
is consistent with previous work that shows bone resorption in response to metastatic cell 
invasion released high amounts ofPDGF, which in turn activate the metastatic cells. This 
is known as the seed and soil hypothesis. 
As a comparison to highly metastatic MDA-MB-231 cell line, we performed a 
similar migration analysis on BT-20 cells. These cell are pre-metastatic and non-invasive 
in vivo. Results are shown in Figure 8-10 (Single Cells) and Figure 8-ll(Spheroid 
Extravasation). Unlike MDA-MB-231 cells, no significant difference is observed 
between single cell and extravasating cell behavior, indicating that autocrine PDGF 
activity is reduced in BT-20 cells compared to MDA-MB-231 cells. In both single ce11 
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and spheroids, BT-20 cells show decreased speed with increased collagen content, 
consistent with other reports and previous data in this study. In all conditions, PDGF 
treatment increased cell speed whereas PDGFR inhibition had virtually no effect. 
8.3.4 MDA-MB-231 
To assess angiogeneic and osteoclast activating potential, VEGF and PtHRP secretion 
from MDA-MB-231 cells was measured via ELISA with or without exogenous PDGF 
application. The results of the ELISA without PDGF administration are shown in Figure 
8;..12 (VEGF) and Figure 8-13 (PtHRP). Contrary to the spheroid growth and migration 
experiments, the results do not show a significant effect of microenvironment on PtHRP 
or VEGF expression. PtHRP expression decreases slightly with increased stiffness, which 
is consistent with previous studies that type 1 collagen inhibits PtHRP expression. 
Similarly, VEGF expression decreased with increasing collagen content, but all samples 
are well above the necessary in vivo levels for activation of angiogeneic cascades. 
8.4 Discussion 
Although the recent development of 3D in vitro cancer models has been a valuable tool 
for researchers, these systems often fail to recapitulate the dynamics of in vivo disease 
progression. The tumor ECM is a dynamic system that has a bidirectional signaling 
relationship with cancer cells, and these interactions must be present in order to produce 
clinically predictive insights. One of the major failing of current 3D culture platforms is 
that they are engineered to recreate one tissue type or one time point in disease 
progression, failing to model the constantly changing properties of the system. Here, we 
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present the use of cancer cell spheroids embedded in type I collagen gels with varying 
collagen content as tissue-specific and disease progression models of cancer cell 
behavior. Stiffer gels are used to simulate a bone tumor, whereas the transition from 
softer to stiffer gels is representative of breast cancer tumor progression. 
Our first goal in presenting this system was to validate that these gels can 
represent a tissue-specific analog, specifically a bone-like environment experienced by 
osteosarcoma cells. To be clear, these gels are not meant to simulate calcified bone, 
which is orders of magnitude less compliant than the gels used here. Bone tumors are not 
calcified, and have stiffness that correlate with the gels employed here305 . The hypothesis 
was that clinically observed cellular behaviors would be present in these stiff gels, but not 
in softer ones. The first metric used was spheroid growth as measured by the diameter of 
the cell mass. U20S cells showed the most growth in the stiffest gels, consistent with 
growth observed in patients. This same growth, in the absence of pro- or anti-
proliferation signaling molecules, was not observed in softer gels, indicating that a stiff 
ECM is required to support aggressive cell growth. When these spheroids were exposed 
to exogenous PDGF, they did not show any appreciable increase in growth speed in any 
of the gels. This is consistent with osteosarcoma cells not responding to PDGF, instead 
secreting their own PDGF analog, osteosarcoma-derived growth factor (ODGF), which 
signals through the PDGF receptor (PDGFR). Consequently, when a PDGFR inhibitor 
was added to the spheroids, growth was severely curtailed in softer gels. This result has 
also been seen in standard 2D assays as well as subcutaneous murine models of 
osteosarcoma. This efficacy was not observed in the Smg/mL gels, indicating that this 
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microenvironment conferred a resistant phenotype on the cells. This is also consistent 
with PDGFR inhibitors tested in clinical trials, which showed little efficacy as anti-
proliferative treatments. 
Although analysis ofU20S migration in collagen gels proved inconclusive, 
protein secretion analysis via ELISA provided further evidence that 5mg/mL gel promote 
in vivo-like cell behavior. U20S cells, and other pre-metastatic osteosarcoma cell lines, 
have very low angiogeneic potential in patients, a behavior which is reflected in the 
minimal amount of secreted VEGF detected from U20S spheroids in 5mg/mL gels. 
Conversely, U20S cells have been shown to induce angiogenesis in a chorioallantoic 
membrane assay. This assay involves implanting a filter disc loaded with U20S cells in 
the embryonic blood vessels of a fertilized chick egg and measuring the resulting vessel 
growth309. The embryonic vessel is a very compliant microenvironment315 , and the 
angiogeneic potential ofU20S cells in a soft matrix is recapitulated in our own results, 
where VEGF secretion is high in 2mg/mL gels. 
The response of U20S cells to different collagen concentrations proves that 
altering the ECM is sufficient to drastically alter cell behavior. Furthermore, this 
differential behavior is consistent with clinical data, suggesting that the 5mg/mL gels are 
a definitively more biomimetic culture system for these cells. This is an important 
insight, as it allows us to use these gels as tissue- or disease-state analogs for more 
complex systems. 
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The microenvironment of breast cancer has been extensively studied, and its role 
in disease development and progression is well accepted103 . Despite this, very few culture 
systems attempt to recreate the dynamic nature of the tumor ECM, which is constantly 
remodeled by both cancer and somatic cells. ECM mechanics and collagen content are 
critical in the development of a tumor; breast tissue with high stiffness and collagen 
content has a higher tumor incidence316. The microenvironment is also altered during 
disease progression, as supported by the observation that stiffer tumors result in poorer 
survival rates104 and tumor stiffness increases with tumor grade317. All ofthis evidence 
indicates that a 3D scaffold for studying breast cancer cell growth can, at best, represent 
an analog of one time point in the tumor life cycle. It is therefore critically important that 
a range of ECM properties be reproduced in vitro as "snapshots" of different disease 
states. Here, we use the type 1 collagen gels with varying collagen content as analogs of 
different stages in breast cancer progression. Softer gels are analogous to early stage or 
even healthy tissue, where the stiffer gels represent the microenvironment encountered by 
late-stage, metastatic cancer318'319. 
We evaluated the potential of embedded spheroids in different collagen gels as a 
disease time point model by using both a pre- and post-metastatic breast cancer cell line. 
We first observed how these cells grow in the different collagen gels. Untreated BT-20 
cells showed a slight preference for softer collagen gels, with spheroids in the 2mg/mL 
gels growing larger than those in 4 and 5mg/mL. MDA MB 231 showed no preference 
for a particular collagen content, consistent with their previously observed ability to grow 
in a variety of tissue types. When PDGF was added to the spheroids, a striking increase in 
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growth rate was observed for both cell lines, but only in gels with lower collagen content. 
In both cases, spheroids embedded in 5mg/mL gels were unaffected by PDGF addition. 
This is consistent with previous studies that PDGF is an active pro-growth signal in early 
stage cancers, but serves as a pro-invasion signal in late-stage cancer with less effect on 
cell growth. 
The role of PDGF as an agonist of cell migration was confirmed when we 
assessed the migration ofMDA-MB-231 away from spheroids in collagen gels. In stiffer 
gels, and only in stiffer gels, PDGF had a pronounced impact on cell speed. This affect 
was not observed when single cells were studied, indicating that this behavior is a result 
of collective Cell Researchponse to PDGF administration. This is consistent with PDGF's 
role as an autocrine signaling molecule affecting the epithelial-to-mesenchymal transition 
which results in more invasive cancer cells. This type of autocrine loop requires a critical 
mass of cells in order to propagate sufficiently, which is a behavior observed in our 
system. BT-20 cells, as a pre-metastatic cell line, would not be expected to undergo this 
invasive switch as they have not accrued enough genetic mutations and signaling 
pathway anomalies. 
Similarly, we observed the ability ofPDGFR inhibitors to affect cell growth and 
migration. In both cell lines, PDGFR inhibitors were ineffective at reducing Cell Motility 
and theity, although this affect may be due to a lack of baseline motility in BT-20 cells. 
Additionally, PDGFR inhibitors showed efficacy in reducing spheroid growth in both cell 
lines, but only in softer collagen gels. There have been numerous reports that a rigid 
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ECM is sufficient to confer resistance to R TK inhibition on cancer cells, a trait that is 
supported by our results. This result is also consistent with the clinical observation that 
RTK inhibitors are fairly efficacious against primary lesions, but fail to reduce metastatic 
incidence or survival rates. 
Here we have strived to show that collagen gels with varying collagen content are 
any appropriate scaffold to study cancer cell behavior and tumor development. The 
benefit of using an embedded spheroid instead of diffusely distributed cells has been 
previously discusses and serves to further increase the clinically predictive nature of the 
result obtained using this system. When embedded bone cancer spheroids are analyzed, 
they exhibit in vivo like behavior, but only in the stiffest gels. In softer gels they exhibit 
behavior seen in other in vitro systems as well as ectopic in vivo assays. These types of 
assays have already proven to be clinically uninformative, indicating that c careful 
consideration must be taken when choosing the 3D matrix or animal protocol used in 
evaluating cancer cell behavior. 
Similarly, these gels with embedded spheroids can be sued to model breast cancer 
disease progression. Post-metastatic MDA-MB-231 breast cancer cell exhibit a PDGF-
sensitive invasiveness, but only in the ECM meant to mimic late stage tumors. In early 
stage ECM mimics, both MDA-MB-231 and the pre-metastatic BT-20 cells show 
increased growth in response to PDGF as well as a sensitivity to a PDGFR inhibitor. 
These results, which mirror the observed behavior of these cell in clinically 
relevant settings, shows that different collagen gels can be used as a powerful tool to 
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model different disease states, allowing for predictive studies to be done cheaply and in a 
high-throughput manner. This type of system would greatly improve current drug 
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Figure 8-1: U20S spheroid growth in different collagen gels. Spheroids showed the 
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Figure 8-2: Migration ofU20S cells diffusely embedded inside collagen gels with 
different collagen content. These speeds are very low, and mostly 
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Figure 8-3: U20S cell migration away from spheroids embedded in collagen gels with 
different collagen content. These data-sets represent a very small n, and 
are most likely statistical aberrations more than true results. 
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Figure 8-4: U20S spheroid and diffuse cell secretion ofVEGF in different collagen 
gels. The lack ofVEGF expression in the stiffest gels is consistent with 


















U20s PtHRP Expression 
2 mg/mL 3 mg/ml 4 mg/ml 5 mg/ml 
Collagen Concentration 
Figure 8-5: U20S spheroid and diffuse cell secretion ofPtHRP in different collagen 
gels. U20S cell expression of PtHRP is insensitive to collagen content, 
but is significantly reduced in the spheroid geometry. 
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MDA-MB-231 Spheroid Growth 
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Figure 8-6: MDA-MB-231 Spheroid growth in different collagen gels in response to 
R TK inhibition and exogenous PDGF treatment. Control spheroids were 
similar across all conditions, but drug treated spheroid showed resistance 
to anti-proliferative affects in stiffer gels. PDGF had a marked effect on 
spheroid growth in softer gels. 
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Figure 8-7: BT-20 Spheroid growth in different collagen gels in response to RTK 
inhibition and exogenous PDGF treatment. Control spheroids were similar 
across all conditions, but drug treated spheroid showed resistance to anti-
proliferative affects in stiffer gels. PDGF had a modest effect on spheroid 
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Figure 8-8: Migration ofMDA-MB-231 cells diffusely embedded inside collagen gels 
with different collagen content. Cells show the expected decrease in speed 
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Figure 8-9: MDA-MB-231 cell migration away from spheroids embedded in collagen 
gels with different collagen content. Cells show similar speeds to single 
cell suspensions, except in the PDGF treated spheroids in stiffer gels. 
PDGF plays a critical role in breast cancer invasion and metastasis in 
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Figure 8-10: Migration ofBT-20 cells diffusely embedded inside collagen gels with 
different collagen content. Cells show the expected decrease in speed with 
increasing steric hindrance of denser collagen networks. 
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Figure 8-11: BT-20 cell migration away from spheroids embedded in collagen gels with 
different collagen content. PDGF increases cell speed in all conditions, 
while PDGFR inhibition has little effect. 
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Figure 8-12: Secretion ofVEGF by MDA-MB-231 spheroids and suspended cells. 
VEGF expression slightly decreases with increasing collagen content, 
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Figure 8-13: Secretion ofPtHRP by MDA-MB-231 spheroids and single cell 
suspensions. PtHRP is critical for bone resorption and metastasis, but also 
play a role in normal breast tissue function. Therefore, it is not surprising 
to find high expression in both environments. Interestingly, secretion of 
PtHRP from softer collagen gels is the only example of increased 
secretion from spheroids compared to single cells. 
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Chapter 9: Conclusions and Future Work 
The ability of tumor cells to resist the effect of chemotherapies has long been a major 
concern of clinical oncologists and researchers alike. Chemoresistance has been 
extensively studied in numerous tumor models, but a complete understanding of the 
numerous proteins and environmental factors that contribute to cancer drug response 
remains elusive. In order to address this knowledge gap, cancer cell behavior and drug 
response must be investigated at the systems level, which necessitates the identification 
of the major effecters of cell fate. In this study, we investigated the role of the cellular 
microenvironment on cancer cell behavior, showing that the extracellular-matrix (ECM) 
properties, cell-adhesion proteins and cell-cell interactions play key roles in 
chemotherapeutic efficacy. 
9.1 Collagen Gel Density Alters Cancer Cell Behavior 
ECM stiffness and cell-ECM adhesions have been shown to be effectors of cell behavior. 
Despite extensive research, the effects of these extracellular conditions on intercellular 
signaling cascades are still poorly understood. To address this knowledge gap, this thesis 
investigates breast and bone cancer Cell Researchponse to PI3K pathway inhibition, and 
how modulating the mechanical and biochemical properties of the in vitro ECM affected 
this response (Chapter 6:). Collagen content within 3D gels was varied to control the 
mechanical environment, and key proteins within the PI3K pathway were assayed via 
western blot. 
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9.1.1 Major Contributions 
The results from this thesis indicate that both high-level cellular behaviors and low-level 
individual protein responses are sensitive to ECM properties. Additionally, reaction of 
these systems to ECM properties is not a simple relationship, demonstrating bimodal and 
nonlinear responses. Similarly to what has been observed in other experiments, ECM 
stiffness correlated with decreased drug sensitivity in the U20s cell line. When 2D and 
3D conditions were compared, the relationship was much more complex, with stiffer 3D 
matrices promoting more robust cells when compared to 2D, but softer ECM promoted 
increased drug sensitivity. The comparison of2D and 3D conditions is more 
straightforward in the MCF7 cell line, with cells grown in 2D being the most sensitive to 
the drug. The effect ofECM mechanics was reversed in MCF7s when compared to 
U20S, as softer gels promoted cellular resistance to the antiproliferative effects ofPBK 
inhibition. These results provide insight into the complex relationship between cancer cell 
and the microenvironment and validate the 3D collagen gel as a model in vitro system for 
future studies. 
9.1.2 Future Work 
While these results contribute to the growing knowledge base on cancer-ECM 
interactions, further investigations are warranted. The range of collagen concentrations 
used was limited, compared to both outside labs and experiments described later in this 
thesis. These more extreme collagen concentrations proved to be of interest in these later 
studies, warranting a return to study the effects of PI3K pathway inhibition in both 
SmglmL and 2mglmL collagen gels. 
142 
9.2 Development of an Embedded Spheroid Model 
Investigations of tumor behavior and preclinical drug assessments are 
increasingly employing 3D culture systems249 . This methodological shift is being 
informed by mounting evidence that these systems produce cellular behavior similar to 
what is seen in vivo, and that this difference is do more faithful microenvironment 
mimicry104•250 . This advantage has shown to produce more predictive results in 3D 
systems when compared to 2D. Most ofthe employed 3D systems come in one of two 
flavors: cell growth on non-adherent scaffold to induce cell-cell association or 
suspending single cells inside a porous natural or artificial scaffold to promote cell-matrix 
attachment251 •252. In this section ofthe thesis (Chapter 7:) we presented a scalable and 
reproducible method for embedding and manipulating cancer cell spheroids inside a 3D 
collagen gel. This spheroid-based model is easy to produce, cost-effective, quantitative, 
and high throughput with low setup time while providing opportunities to study 
proliferation, invasion, enzymatic activity, and antitumor agent activity for clinically 
relevant data acquisition. It builds upon previous spheroid and spheroid-collagen 
models,268- 273 and enables individual spheroid manipulation along with whole spheroid 
and single cell analyses. 
9. 2.1 Major Contributions 
Both cell-ECM and cell-cell interactions are key drivers of normal cell behavior. In the 
context of cancer, these interactions become even more critical in driving the 
development of the disease state. 3D in vitro models of cancer, driven by pioneering 
work in tissue engineering, strives to recapitulate the tumor microenvironment to further 
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study tumor cell behavior. Most models developed with this aim support the development 
of either cell-cell or cell-ECM adhesions, but rarely both. In this study, we design and 
validate the embedded spheroid model, in which a macroscopic cell mass is incorporated 
into a 3D ECM-like environment. Spheroids are robust, and batch-to-batch and intra-
batch variations are acceptably small. Cells in this system are sensitive to advanced drug 
delivery methods, with expansile nanoparticle drug delivery showing greater efficacy in 
reducing spheroid size than simple bolus delivery. These results are consistent with in 
vivo data, but are not recapiatulated in 2D or other 3D models. 
9. 2. 2 Future Work 
Future work should focus on expanding upon the difference in drug response observed 
when using expansile nanoparticles. If this system is appropriate for testing advanced 
drug delivery technologies, then it could provide and invaluable tool for research 
attempting to increase drug efficacy through targeted delivery. Similarly, development of 
the drug themselves could be expedited with the use of a cheap, high throughput, in vitro 
system as a compliment to the array os pre-clinical models currently employed. 
9.3 Embedded Spheroid as a Tissue Specific Analog 
The ability to create biomimetic 3D environments in vitro has been a critical 
development in cancer research168 . It is now well established that the specific properties 
of the culture system used affect cell behavior, including mechanical properties, 
component proteins, integrins-binding ligand density, pore size and growth factor 
content112. Despite our deepening understanding of how these factors contribute to cell 
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behavior, relatively little work has been done on calibrating these properties to a specific 
in vivo condition. It is one thing to design a scaffold with tunable properties, it is quite 
another to set those properties to match a target tissue. The wealth of reports on how 
tissue architecture and microenvironment properties affect cell behavior and disease state 
suggest that such a targeted approach is critical to begin harvesting clinically relevant 
data from these systems36'251 '253 . In this section (Chapter 8:), we use the embedded 
spheroid model developed previously as a tissue-specific analog for the study of cancer 
spheroid behavior. We validate the assertion that specific collagen content represents a 
tissue-specific ECM using the U20S cell line and then sue the system to study pre- and 
post-metastatic breast cancer cell lines. 
9. 3.1 Major Contributions 
Tissue specific metastasis has been observed for decades, but the molecular mechanisms 
remain poorly defined. Most tumors show preferential metastatic potential to a particular 
tissue type, and a high level, predictive understanding of this predilection would aid 
clinical interventions immensely. Here we present and validate a platform for the study of 
this phenomenon, as well as the more general study oftumor-ECM interactions. We 
show that the embedded spheroid model produces results seen in vivo when studying 
receptor tyrosine kinase inhibitors, results that are not recapitulated in 2D. This also 
provides as explanation for both the pre-clinical success and clinical failures of these 
compounds. Furthermore, we use the system to compare pre- and post-metastatic cell 
lines, showing that the post-metastatic cell lines are either proliferative or migratory, but 
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not both, in all conditions, whereas pre-metastatic cells are more active in an orthotopic 
environment, especially when presented with growth factors. 
9.3.2 Future Work 
Future work here should focus on delving into low-level data about the responses 
observed herein. Understanding the forces that affect cell behavior is important, but the 
entire process is still poorly understood and will require a multi-scale approach before 
clinically useful knowledge can be obtained. Analyzing specific protein pathways and 
individual cell behavior, including subpopulations are key pieces of information that are 
still poorly understood or overlooked entirely. The realization of this information well 
could lead to the embedded spheroid model being deployed as a pre-clinical replacement 
for animal xenograft models for drug validation. 
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